AU2006318948A1 - Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors - Google Patents

Description

WO 2007/060404 PCT/GB2006/004327 -1 PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS The present invention relates to compounds, pyrido-, pyrazo- and pyrimido-pyrimidine derivatives, which act as mTOR inhibitors, their use and their synthesis. 5 Background Growth factor/mitogenic activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway ultimately leads to the key cell cycle and growth control regulator mTOR, the mammalian target of rapamycin (alternatively referred to as FRAP (FKBP12 and rapamycin associated protein), RAFT1 (rapamycin and FKBP12 target 1), RAPT1 (rapamycin 10 target 1) - all derived from the interaction with the FK-506-binding protein FKBP12, and SEP (sirolimus effector protein)). mTOR is a mammalian serine/threonine kinase of approximately 289 kDa in size and a member of the evolutionary conserved eukaryotic TOR kinases (refs. 1-4). The mTOR protein is a member of the PI3-kinase like kinase (PIKK) family of proteins due to its C-terminal homology (catalytic domain) with PI3-kinase and the 15 other family members, e.g. DNA-PKcs (DNA dependent protein kinase), ATM (Ataxia telangiectasia mutated). In addition to a catalytic domain in the C-terminus, mTOR contains a FKBP12/rapamycin complex binding domain (FRB). At the N-terminus up to 20 HEAT (Huntingtin, EF3, alpha regulatory subunit of PP2A and TOR) motifs are found whilst more C-terminal is a FAT (FRAP-ATM-TRRAP) domain, and at the extreme C-terminus of the 20 protein an additional FAT domain is found (FAT-C) (refs. 5,6). TOR has been identified as a central regulator of both cell growth (size) and proliferation, which is in part governed by translation initiation. TOR dependant phosphorylation of S6-kinase (S6K1) allows translation of ribosomnal proteins involved in cell cycle progression (refs. 7-9). Cap-dependant translation is regulated by the phosphorylation 25 of the eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1 (PHAS 1)). This modification prevents PHAS-1 binding eIF4E, thereby permitting formation of an active eIF4F translation complex (reviewed in refs. 10,11,12). Activation of these signalling elements is dependant on insulin, other growth factors and nutrients suggesting a gatekeeper role for mTOR in the control of cell cycle progression only under favourable environmental 30 conditions. The PI3KIAKT signalling cascade lies upstream of mTOR and this has been shown to be deregulated in certain cancers and results in growth factor independent activation in, for example, PTEN deficient cells. mTOR lies at the axis of control for this pathway and inhibitors of this kinase (e.g. sirolimus (rapamycin or Rapamune T M ) and everolimus (RAD001 WO 2007/060404 PCT/GB2006/004327 -2 or Certicanm)) are already approved for immunosuppression and drug eluting stents (reviewed in refs. 13, 14), and are now receiving particular interest as novel agents for cancer treatment. Tumour cell growth arises from the deregulation of normal growth control 5 mechanisms such as the loss of tumour suppressor function(s). One such tumour suppressor is the phosphatase and tensin homologue deleted from chromosome ten (PTEN). This gene, also known as mutated in multiple advanced cancers (MMAC), has been shown to play a significant role in cell cycle arrest and is the most highly mutated tumour suppressor after p53. Up to 30% of glioblastoma, endometrial and prostate cancers have somatic mutations or 10 deletions of this locus (refs. 15,16). PI3K converts phosphatidylinositol 4,5, bisphosphate (PIP2) to phosphatidylinositol 3,4,5, triphosphate (PIP3) whilst PTEN is responsible for removing the 3' phosphate from PIP3 producing PIP2. PI3-K and PTEN act to maintain an appropriate level of PIP3 which recruits and thus activates AKT (also known as PKB) and the downstream signalling cascade 15 that is then initiated. In the absence of PTEN, there is inappropriate regulation of this cascade, AKT becomes effectively constitutively activated and cell growth is deregulated. An alternative mechanism for the deregulation of this cell signalling process is the recent identification of a mutant form of the PI3K isoform, p1l0alpha (ref. 17). The apparent increased activity of this mutant is thought to result in increased PIP3 production, presumably 20 in excess of that which the function of PTEN can counteract. Increased signalling from PI3K, thus results in increased signalling to mTOR and consequently, its downstream activators. In addition to the evidence linking mTOR with cell cycle regulation (from G1 to S phase) and that inhibition of mTOR results in inhibition of these regulatory events it has been shown that down regulation of mTOR activity results in cell growth inhibition (Reviewed in 25 refs. 7,18,19). The known inhibitor of mTOR, rapamycin, potently inhibits proliferation or growth of cells derived from a range of tissue types such as smooth muscle, T-cells as well as cells derived from a diverse range of tumour types including rhabdomyosarcoma, neuroblastoma, glioblastoma and medulloblastoma, small cell lung cancer, osteosarcoma, pancreatic carcinoma and breast and prostate carcinoma (reviewed in ref. 20). Rapamycin has 30 been approved and is in clinical use as an immunosuppressant, its prevention of organ rejection being successful and with fewer side effects than previous therapies (refs. 20, 21). Inhibition of mTOR by rapamycin and its analogues (RAD001, CCI-779) is brought about by the prior interaction of the drug with the FK506 binding protein, FKBP 12. Subsequently, the WO 2007/060404 PCT/GB2006/004327 -3 complex of FKBP12/rapamycin then binds to the FRB domain of mTOR and inhibits the downstream signalling from mTOR. The potent but non-specific inhibitors of PI3K, LY294002 and wortmannin, also have been shown to inhibit the kinase function of mTOR but act through targeting the catalytic 5 domain of the protein (ref. 21). Further to the inhibition of mTOR function by small molecules targeted to the kinase domain, it has been demonstrated that kinase dead mTOR cannot transmit the upstream activating signals to the downstream effectors of mTOR, PHAS 1 or p70S6 kinase (ref. 22). It is also shown that not all functions of mTOR are rapamycin sensitive and this may be related to the observation that rapamycin alters the substrate profile 10 of mTOR rather than inhibiting its activity per se (ref. 23). Analysis of the interactions of mTOR with other cellular factors has revealed that in addition to the mTOR-Raptor complex, there is also an mTOR-Rictor complex representing a rapamycin insensitive activity of mTOR (B) (Sarbassov et al. Current Biology, 2004, 14, 1296-1302). This activity likely accounts for the discrepancy between kinase dead mTOR and the alteration of mTOR signalling by 15 rapamycin and its derivatives. The discrepancy also identifies the possibility of a therapeutic advantage in inhibiting directly the catalytic activity of mTOR. It has been suggested that a catalytic inhibitor of mTOR may be a more effective antagonist of cancer cell proliferation and survival and that rapamycin may be more useful in combination with agents that can compensate for its failure to completely disrupt pathway signalling (Choo and Blenis, Cancer 20 Cell, 2006, 9, 77-79; Hay, Cancer Cell, 2005, 8, 179-183). Therefore, it is proposed that a kinase domain directed inhibitor of mTOR may be a more effective inhibitor of mTOR. In addition to rapamycin's ability to induce growth inhibition (cytostasis) in its own right, rapamycin and its derivatives have been shown to potentiate the cytotoxicity of a number of chemotherapies including cisplatin, camptothecin and doxorubicin (reviewed in 25 ref. 20). Potentiation of ionising radiation induced cell killing has also been observed following inhibition of mTOR (ref. 24). Experimental and clinical evidence has shown that rapamycin analogues are showing evidence of efficacy in treating cancer, either alone or in combination with other therapies (see refs. 10, 18, 20). These findings suggest that pharmacological inhibitors of mTOR kinase should be of therapeutic value for treatment of 30 the various forms of cancer comprising solid tumours such as carcinomas and sarcomas and the leukaemias and lymphoid malignancies. In particular, inhibitors of mTOR kinase should be of therapeutic value for treatment of, for example, cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer) and WO 2007/060404 PCT/GB2006/004327 -4 prostate, and of cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva, and of leukaemias (including ALL and CML), multiple myeloma and lymphomas. Renal cell carcinoma in particular, has been identified as sensitive to the rapamycin 5 derivative CCI-779, resulting from a loss of VHL expression (Thomas et al. Nature Medicine, 2006, 12, 122-127). Tumours that have lost the promyelocytic leukaemia (PML) tumour suppressor, have also been shown to be sensitive to inhibition of mTOR by rapamycin as a consequence of disruption of the regulation of the mTOR signalling pathway (Bernadi, Nature, 2006, 442, 779-785) and the use of an mTOR kinase inhibitor in these diseases should 10 be of therapeutic value. These latter examples in addition to those of PTEN deficiency or PI3K mutation indicate where a targeted approach to the use of mTOR inihibitors may prove particularly effective due to an underlying genetic profile, but are not considered to be exclusive targets. Recent studies have revealed a role for mTOR kinase in other diseases (Easton & 15 Houghton, Expert Opinion on Therapeutic Targets, 2004, 8, 551-564). Rapamycin has been demonstrated to be a potent immunosuppressant by inhibiting antigen-induced proliferation of T cells, B cells and antibody production (Sehgal, Transplantation Proceedings, 2003, 35, 7S 14S) and thus mTOR kinase inhibitors may also be useful immunosuppressives. Inhibition of the kinase activity of mTOR may also be useful in the prevention of restenosis, that is the 20 control of undesired proliferation of normal cells in the vasculature in response to the introduction of stents in the treatment of vasculature disease (Morice et al., New England Journal of Medicine, 2002, 346, 1773-1780). Furthermore, the Rapamycin analogue, everolimus, can reduce the severity and incidence of cardiac allograft vasculopathy (Eisen et al., New England Journal of Medicine, 2003, 349, 847-858). Elevated mTOR kinase activity 25 has been associated with cardiac hypertrophy, which is of clinical importance as a major risk factor for heart failure and is a consequence of increased cellular size of cardiomyocytes (Tee & Blenis, Seminars in Cell and Developmental Biology, 2005, 16, 29-37). Thus mTOR kinase inhibitors are expected to be of value in the prevention and treatment of a wide variety of diseases in addition to cancer. 30 The vast majority of mTOR pharmacology to date has focused on inhibition of mTOR via rapamycin or its analogues. However, as noted above, the only non-rapamycin agents that have been reported to inhibit mTOR's activity via a kinase domain targetted mechanism are the small molecule LY294002 and the natural product wortmannin (ref. 21).

WO 2007/060404 PCT/GB2006/004327 -5 Summary of the Invention The present inventors have identified compounds which are ATP-competitive inhibitors of mTOR, and hence are non-rapamycin like in their mechanism of action. Accordingly, the first aspect of the present invention provides a compound of formula 5 I: RN4 RN3 R \NR 6

-

5 x 'X 5 N (I) R -X N '- R wherein: one or two of X 5 , X 6 and X 8 is N, and the others are CH;

R

7 is selected from halo, ORo l , SR s t , NRIRN 2 , NRN 7 aC(=O)Rcl, NRN 7 bSO 2 Rs 2 a, an 10 optionally substituted C 5 -2 0 heteroaryl group, or an optionally substituted C5- 20 aryl group, where Ro t and R s ' are selected from H, an optionally substituted C5- 20 alyl group, an optionally substituted Cs- 20 heteroaryl group, or an optionally substituted C.- 7 alkyl group; R and RN 2 are independently selected from H, an optionally substituted C 1 .- 7 alkyl group, an optionally substituted C5- 20 heteroaryl group, an optionally substituted C5- 20 aryl group or R l 15 and RN 2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms;

R

c d is selected from H, an optionally substituted C 5

-

20 aryl group, an optionally substituted C 5 . 20 heteroaryl group, an optionally substituted C.l- alkyl group or NRN'R N 9 , where R 8 and R 9 are independently selected from H, an optionally substituted C.-7 alkyl group, an optionally 20 substituted C5- 20 heteroaryl group, an optionally substituted C5- 20 aryl group or RN 8 and RN 9 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms;

R

S 2a is selected from H, an optionally substituted C 5

-

20 aryl group, an optionally substituted

C

5

-

2 0 heteroaryl group, or an optionally substituted C1-7. alkyl group; 25 R N 7a and RN7b are selected from H and a C 1

-

4 alkyl group;

RN

3 and RN 4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms;

R

2 is selected from H, halo, ORO 2 , SRs 2 b, NRNSRN 6 , an optionally substituted C 5

-

2 0 heteroaryl group, and an optionally substituted C 5

-

2 0 aryl group, 30 wherein RO 2 and RS 2 b are selected from H, an optionally substituted C 5

-

20 aryl group, an optionally substituted C 5

-

20 heteroaryl group, or an optionally substituted C7., alkyl group;; WO 2007/060404 PCT/GB2006/004327 -6 RNs and RN 6 are independently selected from H, an optionally substituted C.-7 alkyl group, an optionally substituted C 5

-

20 heteroaryl group, and an optionally substituted C 5

-

20 aryl group, or

R

N5 and RN 6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, 5 or a pharmaceutically acceptable salt thereof, with the proviso that when R2 is unsubstituted morpholino, RN 3 and RN 4 together with the nitrogen atom to which they are attached form an unsubstituted morpholino and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not N and X 8 is not CH, or X 6 is not CH and

X

8 is not N, and 10 when R 2 is unsubstituted piperidinyl, RN 3 and RN 4 together with the nitrogen atom to which they are attached form an unsubstituted piperidinyl and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not CH and X 8 is not N. In one embodiment of the first aspect, when R 2 is unsubstituted morpholino, RN 3 and

RN

4 together with the nitrogen atom to which they are attached form an unsubstituted 15 morpholino, R 7 is unsubstituted morpholino or di-methylamino, and X 6 is CH, then X 5 is not N and X 8 is not CH, or X 5 is not CH and X 8 is not N. In another embodiment of the first aspect, when R 2 is unsubstituted piperazino or N formyl piperazino, RN 3 and RN 4 together with the nitrogen atom to which they are attached form an unsubstituted morpholino, unsubstituted piperidinyl or unsubstituted 20 oxidothiomorpholino, R 7 is unsubstituted morpholino or benzylamino, and X 6 is CH, then X 5 is not N and X 8 is not CH, or X 5 is not CH and X 8 is not N. In another embodiment of the first aspect, when R 2 is unsubstituted morpholino, unsubstituted piperidino, unsubstituted pyrrolidino, RN 3 and RN 4 together with the nitrogen atom to which they are attached form a morpholino, piperazinyl, unsubstituted piperidinyl or 25 unsubstituted pyrrolidinyl, R 7 is unsubstituted morpholino, unsubstituted piperidinyl, unsubstituted pyrrolidinyl, and X 5 is CH, then X 6 is not N and X 8 is not CH, or X 6 is not CH and X 8 is not N. According to a second aspect of the present invention there is provided a compound of formula I(A): WO 2007/060404 PCT/GB2006/004327 -7 N4 RN3 R 0N NH X N NN ' I(A) wherein: one or two of X 5 , X 6 and X 8 is N, and the others are CH;

R

N3 and RN 4 , together with the nitrogen to which they are bound, form a heterocyclic ring 5 containing between 3 and 8 ring atoms;

R

2 is selected from H, halo, ORO 2 , SRS 2 b, NRNSRN 6 , an optionally substituted C 5

-

20 heteroaryl group, and an optionally substituted C5- 20 aryl group, wherein RO 2 and RS 2 b are selected from H, an optionally substituted C5- 20 aryl group, an optionally substituted C 5

-

20 heteroaryl group, or an optionally substituted C.- 7 alkyl group; RNs 5 10 and RN 6 are independently selected from H, an optionally substituted C.-7 alkyl group, an optionally substituted C 5

-

2 0 heteroaryl group, and an optionally substituted C5- 20 aryl group, or

RN

5 and RN 6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms;

R

o 3 is selected from hydrogen or an optionally substituted Cl-6 alkyl group; and 15 R N10 is selected from C(=0)Rc 2 , C(=S)Rc 3 , SO 2 Rs 3 , an optionally substituted C5-20 heteroaryl group, an optionally substituted C5- 20 aryl group, or an optionally substituted C 1

-

1 0 alkyl group where RC 2 and RC 3 are selected from H, an optionally substituted C5-.

20 aryl group, an optionally substituted C5- 20 heteroaryl group, an optionally substituted Ci.

7 alkyl group or NRNI lR 2 , where RN l and RNI 2 are independently selected from H, an optionally substituted 20 C.I-7 alkyl group, an optionally substituted C5- 20 heteroaryl group, an optionally substituted

C

5

-

20 aryl group or R1 and RNI 2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; and R S 3 is selected from H, an optionally substituted C5- 20 aryl group, an optionally substituted C 5

-

20 heteroaryl group, or an optionally substituted C .- 7 alkyl group, 25 or a pharmaceutically acceptable salt thereof. According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound of formula 1 or 1(A), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

WO 2007/060404 PCT/GB2006/004327 -8 According to a further aspect of the present invention there is provided of formula 1 or 1(A), or a pharmaceutically acceptable salt thereof, for use in a method of treatment of the human or animal body. According to a further aspect of the present invention there is provided the use of a 5 compound of formula 1 or 1(A), or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease ameliorated by the inhibition of mTOR. Further aspects of the invention provide the use of a compound of formula 1 or 1(A), or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of: cancer, immuno-suppression, immune tolerance, autoimmune disease, 10 inflammation, bone loss, bowel disorders, hepatic fibrosis, hepatic necrosis, rheumatoid arthritis, restenosis, cardiac allograft vasculopathy, psoriasis, beta-thalassaemia, and ocular conditions such as dry eye. mTOR inhibitors may also be effective as antifungal agents. We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt thereof, are effective anti-cancer agents which property is 15 believed to arise from their mTOR inhibitory properties. Accordingly the compounds of the present invention are expected to be useful in the treatment of diseases or medical conditions mediated alone or in part by mTOR, i.e. the compounds may be used to produce a mTOR inhibitory effect in a warm-blooded animal in need of such treatment. Thus the compounds of the present invention provide a method for treating cancer 20 characterised by inhibition of mTOR, i.e. the compounds may be used to produce an anti cancer effect mediated alone or in part by the inhibition of mTOR. Such a compound of the invention is expected to possess a wide range of anti-cancer properties as activating mutations in mTOR have been observed in many human cancers, including but not limited to, melanoma, papillary thyroid tumours, cholangiocarcinomas, 25 colon, ovarian and lung cancers. Thus it is expected that a compound of the invention will possess anti-cancer activity against these cancers. It is in addition expected that a compound of the present invention will possess activity against a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas in tissues such as the liver, kidney, bladder, prostate, breast and pancreas. In particular such compounds of the invention 30 are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the skin, colon, thyroid, lungs and ovaries. More particularly such compounds of the invention, or a pharmaceutically acceptable salt thereof, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with mTOR, especially those WO 2007/060404 PCT/GB2006/004327 -9 tumours which are significantly dependent on mTOR for their growth and spread, including for example, certain tumours of the skin, colon, thyroid, lungs and ovaries. Particularly the compounds of the present invention are useful in the treatment of melanomas. Thus according to this aspect of the invention there is provided a compound of the 5 formula I or 1(A), or a pharmaceutically acceptable salt thereof, as defined herein for use as a medicament. According to a further aspect of the invention there is provided the use of a compound of the formula I or I(A), or a pharmaceutically acceptable salt thereof, as defined herein in the manufacture of a medicament for use in the production of a mTOR inhibitory effect in a 10 warm-blooded animal such as man. According to this aspect of the invention there is provided the use of a compound of the formula I or I(A), or a pharmaceutically acceptable salt thereof, as defined herein in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as man. 15 According to a further feature of the invention, there is provided the use of a compound of the formula I or I(A), or a pharmaceutically acceptable salt thereof, as defined herein in the manufacture of a medicament for use in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, 20 breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries. According to a further aspect of the invention there is provided the use of a compound of the formula I or I(A), or a pharmaceutically acceptable salt thereof, as defined herein in the production of a mTOR inhibitory effect in a warm-blooded animal such as man. 25 According to this aspect of the invention there is provided the use of a compound of the formula I or I(A), or a pharmaceutically acceptable salt thereof, as defined herein in the production of an anti-cancer effect in a warm-blooded animal such as man. According to a further feature of the invention, there is provided the use of a compound of the formula I or I(A), or a pharmaceutically acceptable salt thereof, as defined 30 herein in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries.

WO 2007/060404 PCT/GB2006/004327 - 10 According to a further feature of this aspect of the invention there is provided a method for producing a mTOR inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I or I(A), or a pharmaceutically acceptable salt thereof, as defined 5 herein. According to a further feature of this aspect of the invention there is provided a method for producing an anti-cancer effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I or I(A), or a pharmaceutically acceptable salt thereof, as defined 10 herein. According to an additional feature of this aspect of the invention there is provided a method of treating melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid 15 tumours of the skin, colon, thyroid, lungs and ovaries, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I or I(A) or a pharmaceutically acceptable salt thereof as defined herein. In a further aspect of the invention there is provided a pharmaceutical composition 20 which comprises a compound of the formula I or I(A), or a pharmaceutically acceptable salt thereof, as defined herein in association with a pharmaceutically-acceptable diluent or carrier for use in the production of a mTOR inhibitory effect in a warm-blooded animal such as man. In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula I or I(A), or a pharmaceutically acceptable salt 25 thereof, as defined herein in association with a pharmaceutically-acceptable diluent or carrier for use in the production of an anti-cancer effect in a warm-blooded animal such as man. In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula I or I(A), or a pharmaceutically acceptable salt thereof, as defined herein in association with a pharmaceutically-acceptable diluent or carrier 30 for use in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and WO 2007/060404 PCT/GB2006/004327 -11 recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries in a warm-blooded animal such as man. Another further aspect of the invention provides for the use of a compound of formula 1 or 1(A), or a pharmaceutically acceptable salt thereof, in the preparation of a medicament 5 for use as an adjunct in cancer therapy or for potentiating tumour cells for treatment with ionizing radiation or chemotherapeutic agents. Other further aspects of the invention provide for the treatment of disease ameliorated by the inhibition of mTOR, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of formula 1 or 1(A), or a pharmaceutically 10 acceptable salt thereof, preferably in the form of a pharmaceutical composition and the treatment of cancer, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound as defined in the first or second aspect in combination, preferably in the form of a pharmaceutical composition, simultaneously or sequentially with ionizing radiation or chemotherapeutic agents. 15 Definitions The term "aromatic ring" is used herein in the conventional sense to refer to a cyclic aromatic structure, that is, a structure having delocalised >-electron orbitals. Nitrogen-containing heterocyclic ring having from 3 to 8 ring atoms: The term 20 "Nitrogen-containing heterocyclic ring having from 3 to 8 ring atoms" as used herein refers to a 3 to 8 membered heterocylic ring containing at least one nitrogen ring atom. The term "together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms" as used herein refers to a 3 to 8 membered heterocylic ring containing at least one nitrogen ring atom. Examples of these groups include, but are not 25 limited to: NI: aziridine (C 3 ), azetidine (C 4 ), pyrrolidine (tetrahydropyrrole) (C 5 ), pyrroline (e.g., 3-pyrroline, 2,5-dihydropyrrole) (C 5 ), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole)

(C

5 ), piperidine (C 6 ), dihydropyridine (C 6 ), tetrahydropyridine (C 6 ), azepine (C 7 );

N

2 : imidazolidine (Cs), pyrazolidine (diazolidine) (C 5 ), imidazoline (Cs), pyrazoline 30 (dihydropyrazole) (C 5 ), piperazine (C 6 );

N

1 0 1 I: tetrahydrooxazole (Cs), dihydrooxazole (Cs), tetrahydroisoxazole (Cs), dihydroisoxazole (C 5 ), morpholine (C 6 ), tetrahydrooxazine (C 6 ), dihydrooxazine (C 6 ), oxazine (C 6

);

WO 2007/060404 PCT/GB2006/004327 - 12 NISi: thiazoline (C 5 ), thiazolidine (Cs), thiomorpholine (C 6 );

N

2 0 1 : oxadiazine (C 6 );

N

1 0 1 Si 1 : oxathiazine (C 6 ). Alkyl: The term "alkyl" as used herein, pertains to a monovalent moiety obtained by 5 removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 20 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g. partially unsaturated, fully unsaturated). Thus, the term "alkyl" includes the sub-classes alkenyl, alkynyl, cycloalkyl, cycloalkyenyl, cylcoalkynyl, etc., discussed below. 10 In the context of alkyl groups, the prefixes (e.g. Cl- 4 , C- 7 , C 1 -2 0 , C2- 7 , C3- 7 , etc.) denote the number of carbon atoms, or range of number of carbon atoms. For example, the term

"CI-

4 alkyl", as used herein, pertains to an alkyl group having from 1 to 4 carbon atoms. Examples of groups of alkyl groups include C 1

-

4 alkyl ("lower alkyl"), Ci-7 alkyl, and Cl- 20 alkyl. Note that the first prefix may vary according to other limitations; for example, for 15 unsaturated alkyl groups, the first prefix must be at least 2; for cyclic alkyl groups, the first prefix must be at least 3; etc. Examples of (unsubstituted) saturated alkyl groups include, but are not limited to, methyl (CI), ethyl (C 2 ), propyl (C 3 ), butyl (C 4 ), pentyl (C 5 ), hexyl (C 6 ), heptyl (C 7 ), octyl (C 8 ), nonyl (C 9 ), decyl (Clo), undecyl (ClI), dodecyl (CI 2 ), tridecyl (C 1 3 ), tetradecyl (C 1 4 ), 20 pentadecyl (Cs 1 5 ), and eicodecyl (C 2 0 ). Examples of (unsubstituted) saturated linear alkyl groups include, but are not limited to, methyl (CI), ethyl (C 2 ), n-propyl (C 3 ), n-butyl (C 4 ), n-pentyl (amyl) (Cs), n-hexyl (C 6 ), and n-heptyl (C 7 ). Examples of (unsubstituted) saturated branched alkyl groups include iso-propyl (C 3 ), 25 iso-butyl (C 4 ), sec-butyl (C 4 ), tert-butyl (C 4 ), iso-pentyl (Cs), and neo-pentyl (C 5 ). Alkenyl: The term "alkenyl", as used herein, pertains to an alkyl group having one or more carbon-carbon double bonds. Examples of groups of alkenyl groups include C 24 alkenyl, C 2

.-

7 alkenyl, C 2

-

20 alkenyl. Examples of (unsubstituted) unsaturated alkenyl groups include, but are not limited to, 30 ethenyl (vinyl, -CH=CH 2 ), 1-propenyl (-CH=CH-CH 3 ), 2-propenyl (allyl, -CH-CH=CH 2 ), isopropenyl (1-methylvinyl, -C(CH 3

)=CH

2 ), butenyl (C 4 ), pentenyl (Cs), and hexenyl (C 6

).

WO 2007/060404 PCT/GB2006/004327 - 13 Alkynyl: The term "alkynyl", as used herein, pertains to an alkyl group having one or more carbon-carbon triple bonds. Examples of groups of alkynyl groups include C 2

.-

4 alkynyl,

C

2 -7 alkynyl, C 2 -2 0 alkynyl. Examples of (unsubstituted) unsaturated alkynyl groups include, but are not limited to, 5 ethynyl (ethinyl, -C=CH) and 2-propynyl (propargyl, -CH 2 -C=CH). Cycloalkyl: The term "cycloalkyl", as used herein, pertains to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a carbocyclic ring of a carbocyclic compound, which carbocyclic ring may be saturated or unsaturated (e.g. partially unsaturated, fully unsaturated), which 10 moiety has from 3 to 20 carbon atoms (unless otherwise specified), including from 3 to 20 ring atoms. Thus, the term "cycloalkyl" includes the sub-classes cycloalkenyl and cycloalkynyl. Preferably, each ring has from 3 to 7 ring atoms. Examples of groups of cycloalkyl groups include C 3

-

20 cycloalkyl, C 3

-

1 5 cycloalkyl, C 3

-

1 0 cycloalkyl, C 3 -7 cycloalkyl. Examples of cycloalkyl groups include, but are not limited to, those derived from: 15 saturated monocyclic hydrocarbon compounds: cyclopropane (C 3 ), cyclobutane (C 4 ), cyclopentane (C 5 ), cyclohexane (C 6 ), cycloheptane (C 7 ), methylcyclopropane (C 4 ), dimethylcyclopropane (C 5 ), methylcyclobutane (Cs), dimethylcyclobutane (C 6 ), methylcyclopentane (C 6 ), dimethylcyclopentane (C7), methylcyclohexane (C 7 ), dimethylcyclohexane (C 8 ), menthane (Co); 20 unsaturated monocyclic hydrocarbon compounds: cyclopropene (C 3 ), cyclobutene (C 4 ), cyclopentene (Cs), cyclohexene (C 6 ), methylcyclopropene (C 4 ), dimethylcyclopropene (Cs), methylcyclobutene (Cs), dimethylcyclobutene (C 6 ), methylcyclopentene (C 6 ), dimethylcyclopentene (C 7 ), mnethylcyclohexene (C 7 ), dimethylcyclohexene (C 8 ); 25 saturated polycyclic hydrocarbon compounds: thujane (CI 0 ), carane (Cl 0 ), pinane (Co 10 ), bornane (Co 10 ), norcarane (C 7 ), norpinane (C 7 ), norbornane (C 7 ), adamantane

(CO

10 ), decalin (decahydronaphthalene) (CIo); unsaturated polycyclic hydrocarbon compounds: camphene (C 1 o), limonene (C 1 o), pinene (Clo); 30 polycyclic hydrocarbon compounds having an aromatic ring: indene (C 9 ), indane (e.g., 2,3-dihydro-1H-indene) (C 9 ), tetraline (1,2,3,4-tetrahydronaphthalene) (CIo), acenaphthene (C 1 2 ), fluorene (CI 3 ), phenalene (C 13 ), acephenanthrene (C5is), aceanthrene (C16), cholanthrene (C 20

).

WO 2007/060404 PCT/GB2006/004327 -14 Heterocyclyl: The term "heterocyclyl", as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms (unless otherwise specified), of which from 1 to 10 are ring heteroatoms. Preferably, each ring has from 3 to 7 ring atoms, of which from 1 to 4 5 are ring heteroatoms. In this context, the prefixes (e.g. C 3

-

20 , C3- 7 , C5-6, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term "C 5

-

6 heterocyclyl", as used herein, pertains to a heterocyclyl group having 5 or 6 ring atoms. Examples of groups of heterocyclyl groups include C 3

-

20 heterocyclyl, C5- 20 10 heterocyclyl, C 3 -1 5 heterocyclyl, C5- 15 heterocyclyl, C 3 -1 2 heterocyclyl, C 5 s- 1 2 heterocyclyl, C 3

-

1 0 heterocyclyl, C 5

-

1 0 heterocyclyl, C 3

.-

7 heterocyclyl, Cs.5-7 heterocyclyl, and C 5 -6 heterocyclyl. Examples of monocyclic heterocyclyl groups include, but are not limited to, those derived from:

N

1 : aziridine (C 3 ), azetidine (C 4 ), pyrrolidine (tetrahydropyrrole) (C 5 ), pyrroline (e.g., 15 3-pyrroline, 2,5-dihydropyrrole) (Cs), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole) (Cs), piperidine (C 6 ), dihydropyridine (C 6 ), tetrahydropyridine (C 6 ), azepine (C 7 ); Oi: oxirane (C 3 ), oxetane (C 4 ), oxolane (tetrahydrofuran) (C 5 ), oxole (dihydrofuran)

(C

5 ), oxane (tetrahydropyran) (C 6 ), dihydropyran (C 6 ), pyran (C 6 ), oxepin (C 7 ); Si: thiirane (C 3 ), thietane (C 4 ), thiolane (tetrahydrothiophene) (Cs), thiane 20 (tetrahydrothiopyran) (C 6 ), thiepane (C 7 ); 02: dioxolane (C 5 ), dioxane (C 6 ), and dioxepane (C 7 ); 03: trioxane (C 6 );

N

2 : imidazolidine (Cs), pyrazolidine (diazolidine) (Cs), imidazoline (Cs), pyrazoline (dihydropyrazole) (Cs), piperazine (C 6 ); 25 NIOl: tetrahydrooxazole (Cs), dihydrooxazole (Cs), tetrahydroisoxazole (Cs), dihydroisoxazole (Cs), morpholine (C 6 ), tetrahydrooxazine (C 6 ), dihydrooxazine (C 6 ), oxazine (C 6 );

N

I

S,: thiazoline (Cs), thiazolidine (C 5 ), thiomorpholine (C 6 );

N

2 0 1 : oxadiazine (C 6 ); 30 OS 1 St: oxathiole (Cs) and oxathiane (thioxane) (C 6 ); and,

NIOS

1 0SI: oxathiazine (C 6 ). Examples of substituted (non-aromatic) monocyclic heterocyclyl groups include those derived from saccharides, in cyclic form, for example, furanoses (C 5 ), such as WO 2007/060404 PCT/GB2006/004327 - 15 arabinofuranose, lyxofuranose, ribofuranose, and xylofuranse, and pyranoses (C 6 ), such as allopyranose, altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose, galactopyranose, and talopyranose. Spiro-C 3 7 cycloalkyl or heterocyclyl: The term "spiro C 3 -7 cycloalkyl or heterocyclyl" 5 as used herein, refers to a C 3

.-

7 cycloalkyl or C 3 -7 heterocyclyl ring joined to another ring by a single atom common to both rings.

C

5

-

20 aryl: The term "C 5 -2 0 aryl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of a Cs-20 aromatic compound, said compound having one ring, or two or more rings (e.g., fused), and having 10 from 5 to 20 ring atoms, and wherein at least one of said ring(s) is an aromatic ring. Preferably, each ring has from 5 to 7 ring atoms. The ring atoms may be all carbon atoms, as in "carboaryl groups" in which case the group may conveniently be referred to as a "C 5

-

20 carboaryl" group. Examples of C 5

-

20 aryl groups which do not have ring heteroatoms (i.e. C 5

-

20 carboaryl 15 groups) include, but are not limited to, those derived from benzene (i.e. phenyl) (C 6 ), naphthalene (Co 10 ), anthracene (C 1 4 ), phenanthrene (C 1 4 ), and pyrene (C 16 ). Alternatively, the ring atoms may include one or more heteroatoms, including but not limited to oxygen, nitrogen, and sulfur, as in "heteroaryl groups". In this case, the group may conveniently be referred to as a "C5-20 heteroaryl" group, wherein "C 5

-

20 " denotes ring atoms, 20 whether carbon atoms or heteroatoms. Preferably, each ring has from 5 to 7 ring atoms, of which from 0 to 4 are ring heteroatoms. Examples of C 5

-

20 heteroaryl groups include, but are not limited to, C 5 heteroaryl groups derived from furan (oxole), thiophene (thiole), pyrrole (azole), imidazole (1,3-diazole), pyrazole (1,2-diazole), triazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, tetrazole 25 and oxatriazole; and C 6 heteroaryl groups derived from isoxazine, pyridine (azine), pyridazine (1,2-diazine), pyrimidine (1,3-diazine; e.g., cytosine, thymine, uracil), pyrazine (1,4-diazine) and triazine. The heteroaryl group may be bonded via a carbon or hetero ring atom. Examples of C5- 20 heteroaryl groups which comprise fused rings, include, but are not 30 limited to, C 9 heteroaryl groups derived from benzofuran, isobenzofuran, benzothiophene, indole, isoindole; C 0 lo heteroaryl groups derived from quinoline, isoquinoline, benzodiazine, pyridopyridine; C l 4 heteroaryl groups derived from acridine and xanthene.

WO 2007/060404 PCT/GB2006/004327 -16 The above defined groups eg alkyl, heterocyclyl, aryl etc, whether alone or part of another substituent, may themselves optionally be substituted with one or more groups selected from themselves and the additional substituents listed below. Halo: -F, -Cl, -Br, and -I. 5 Hydroxy: -OH. Ether: -OR, wherein R is an ether substituent, for example, a C.- 7 alkyl group (also referred to as a C.I-7 alkoxy group), a C 3

-

20 heterocyclyl group (also referred to as a C 3

-

20 heterocyclyloxy group), or a C 5

-

20 aryl group (also referred to as a C5- 20 aryloxy group), preferably a C 1

-

7 alkyl group. 10 Nitro: -NO 2 . Cyano (nitrile, carbonitrile): -CN. Acyl (keto): -C(=0)R, wherein R is an acyl substituent, for example, H, a Ci-7 alkyl group (also referred to as CI-7 alkylacyl or C 1

-

7 alkanoyl), a C 3

-

20 heterocyclyl group (also referred to as C 3

-

20 heterocyclylacyl), or a Cs- 20 aryl group (also referred to as Cs-2 0 arylacyl), 15 preferably a C 1

.-

7 alkyl group. Examples of acyl groups include, but are not limited to,

-C(=O)CH

3 (acetyl), -C(=O)CH 2

CH

3 (propionyl), -C(=O)C(CH 3

)

3 (butyryl), and -C(=O)Ph (benzoyl, phenone). Carboxy (carboxylic acid): -COOH. Ester (carboxylate, carboxylic acid ester, oxycarbonyl): -C(=0)OR, wherein R is an 20 ester substituent, for example, a Ct- 7 alkyl group, a C3- 20 heterocyclyl group, or a Cs- 20 aryl group, preferably a C.I- 7 alkyl group. Examples of ester groups include, but are not limited to,

-C(=O)OCH

3 , -C(=O)OCH 2

CH

3 , -C(=O)OC(CH 3

)

3 , and -C(=O)OPh. Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide): -C(=O)NR'R, wherein R' and R 2 are independently amino substituents, as defined for amino groups. Examples of 25 amido groups include, but are not limited to, -C(=O)NH 2 , -C(=O)NHCH 3 , -C(=O)N(CH 3

)

2 ,

-C(=O)NHCH

2

CH

3 , and -C(=O)N(CH 2

CH

3

)

2 , as well as amido groups in which R' and R 2 , together with the nitrogen atom to which they are attached, form a heterocyclic structure as in, for example, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, and piperazinylcarbonyl. 30 Amino: -NR'R 2 , wherein R 1 and R 2 are independently amino substituents, for example, hydrogen, a CI.

7 alkyl group (also referred to as C 1

-

7 alkylamino or di-Cl.

7 alkylamino), a C 3

-

20 heterocyclyl group, or a Cs 5

-

20 aryl group, preferably H or a CI.

7 alkyl group, or, in the case of a "cyclic" amino group, R' and R 2 , taken together with the nitrogen WO 2007/060404 PCT/GB2006/004327 -17 atom to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Examples of amino groups include, but are not limited to, -NH 2 , -NHCH 3 , -NHCH(CH 3

)

2 ,

-N(CH

3

)

2 , -N(CH 2

CH

3

)

2 , and -NHPh. Examples of cyclic amino groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidino, piperazinyl, perhydrodiazepinyl, 5 morpholino, and thiomorpholino. The cylic amino groups may be substituted on their ring by any of the substituents defined here, for example carboxy, carboxylate and amido. Acylamido (acylamino): -NR 1

C(=O)R

2 , wherein R' is an amide substituent, for example, hydrogen, a CI-7 alkyl group, a C 3

-

20 heterocyclyl group, or a C5- 20 aryl group, preferably H or a Ci- 7 alkyl group, most preferably H, and R is an acyl substituent, for 10 example, a C 1

-

7 alkyl group, a C 3

-

20 heterocyclyl group, or a C5- 20 aryl group, preferably a C 1 -7 alkyl group. Examples of acylamide groups include, but are not limited to, -NHC(=O)CH 3 ,

-NHC(=O)CH

2

CH

3 , and -NHC(=O)Ph. R 1 and R 2 may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, and phthalimidyl: ONO 'ICY/ succinimidyl maleimidyl phthalimidyl 15 Ureido: -N(R')CONR 2

R

3 wherein R 2 and R 3 are independently amino substituents, as defined for amino groups, and R1 is a ureido substituent, for example, hydrogen, a C 1

.

7 alkyl group, a C 3 .- 20heterocyclyl group, or a Cs5-20aryl group, preferably hydrogen or a Ci.

7 alkyl group. Examples of ureido groups include, but are not limited to, -NHCONH 2 , NHCONHMe, -NHCONHEt, -NHCONMe 2 , -NHCONEt 2 , -NMeCONH 2 , -NMeCONHMe, 20 -NMeCONHEt, -NMeCONMe 2 , -NMeCONEt 2 and -NHC(=0)NHPh. Acyloxy (reverse ester): -OC(=O)R, wherein R is an acyloxy substituent, for example, a CI- 7 alkyl group, a C 3

-

20 heterocyclyl group, or a C 5

-

20 aryl group, preferably a C 1

I.-

7 alkyl group. Examples of acyloxy groups include, but are not limited to, -OC(=O)CH 3 (acetoxy), OC(=O)CH 2

CH

3 , -OC(=O)C(CH 3

)

3 , -OC(=O)Ph, -OC(=O)C 6

H

4 F, and -OC(=0)CH 2 Ph. 25 Thiol : -SH. Thioether (sulfide): -SR, wherein R is a thioether substituent, for example, a Ci- 7 alkyl group (also referred to as a CI-7 alkylthio group), a C 3

-

20 heterocyclyl group, or a C5- 20 aryl group, preferably a CI.

7 alkyl group. Examples of C 1

.

7 alkylthio groups include, but are not limited to, -SCH 3 and -SCH 2

CH

3

.

WO 2007/060404 PCT/GB2006/004327 -18 Sulfoxide (sulfinyl): -S(=O)R, wherein R is a sulfoxide substituent, for example, a CI-7 alkyl group, a C 3

-

20 heterocyclyl group, or a C 5

-

20 aryl group, preferably a Cj.

7 alkyl group. Examples of sulfoxide groups include, but are not limited to, -S(=O)CH 3 and -S(=O)CH 2

CH

3 . Sulfonyl (sulfone): -S(=O) 2 R, wherein R is a sulfone substituent, for example, a Ci-7 5 alkyl group, a C 3

-

20 heterocyclyl group, or a C5- 20 aryl group, preferably a C 1

-

7 alkyl group. Examples of sulfone groups include, but are not limited to, -S(=0) 2

CH

3 (methanesulfonyl, mesyl), -S(=O) 2

CF

3 , -S(=0) 2

CH

2

CH

3 , and 4-methylphenylsulfonyl (tosyl). Thioamido (thiocarbamyl): -C(=S)NR'R 2 , wherein R I and R 2 are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not 10 limited to, -C(=S)NH 2 , -C(=S)NHCH 3 , -C(=S)N(CH 3

)

2 , and -C(=S)NHCH 2

CH

3 . Sulfonamino: -NR'S(=0) 2 R, wherein R 1 is an amino substituent, as defined for amino groups, and R is a sulfonamino substituent, for example, a Ci- 7 alkyl group, a C 3

-.

2 heterocyclyl group, or a Cs.-20aryl group, preferably a CI- 7 alkyl group. Examples of sulfonamino groups include, but are not limited to, -NHS(=O) 2

CH

3 , -NHS(=O) 2 Ph and -N(CH 3 )S(=0) 2

C

6 Hs. 15 As mentioned above, the groups that form the above listed substituent groups, e.g. C 1 .- 7 alkyl, C 3

-

20 heterocyclyl, and C 5

-

20 aryl, may themselves be substituted. Thus, the above definitions cover substituent groups which are substituted. Accordingly, a further aspect of the present invention provides a compound of formula I: N4 N3 R RN 5 20 R X N R wherein: one or two of X 5 , X 6 and X 8 is N, and the others are CH;

R

7 is halo, OR o1 , SR s l , NRNIRN 2 , NRN 7 aC(=O)Rcl, NRN 7 bSO 2 Rs 2a , a C5- 20 heteroaryl group optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, 25 carboxy, and thiol, or Ci.

7 alkyl, C 2

-

7 alkenyl, C 2

.

7 alkynyl, C3.

7 cycloalkyl, C 3

-

7 cycloalkenyl,

C

3 .- 20heterocyclyl, Cs5-20oaryl, Cs.5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol,

C

1

.

7 alkyl, C 2 -7alkenyl, C 2

.-

7 alkynyl, C 3

.

7 cycloalkyl, C 3

.-

7 cycloalkenyl, C 3 .- 20heterocyclyl, 30 C 5 .- 20aryl, Cs5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino), or a C 5

-

2 0 aryl group optionally WO 2007/060404 PCT/GB2006/004327 - 19 substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or C 1i.

7 alkyl, C 2

-

7 alkenyl, C 2 -7alkynyl, C 3

_

7 cycloalkyl, C 3 _cycloalkenyl, C3-2oheterocyclyl, C5-20aryl, C5- 20 heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally 5 substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, CI-7alkyl, C 2

-

7 alkenyl, C 2

.-

7 alkynyl, C3.

7 cycloalkyl, C 3

.-

7 cycloalkenyl, C 3 -20heterocyclyl,

C

5 -20aryl, C 5 -2oheteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino), where Rol and R s ' are H, a C 5

-

20 aryl group, a C 5

-

2 0 heteroaryl group, or a CI- 7 alkyl group 10 where each C1- 7 alkyl, C5-20heteroaryl, or C 5 -20aryl is optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or C1I 7 alkyl,

C

2 -7alkenyl, C 2

-

7 alkynyl, C 3 .- 7cycloalkyl, C 3 -7cycloalkenyl, C3-20heterocyclyl, C 5 -20aryl,

C

5 -20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more 15 groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, CI- 7 alkyl, C 2 -7alkenyl,

C

2

-

7 alkynyl, C 3

.

7 cycloalkyl, C 3

.

7 cycloalkenyl, C 3 -20heterocyclyl, C5-20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino); RNl and RN 2 are independently H, a CI-7alkyl group, a C5-20heteroaryl group, a C 5

-

20 aryl 20 group or R and RN 2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, where each C 1

.

7 alkyl, C5-20heteroaryl, C 5 -20aryl or heterocyclic is optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or C 1

.

7 alkyl, C 2

.

7 alkenyl, C 2 -7alkynyl, C 3

-

7 cycloalkyl,

C

3 -7cycloalkenyl, C 3 .- 20heterocyclyl, Cs5-20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, 25 acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, Cl- 7 alkyl, C 2

-

7 alkenyl, C2-7alkynyl, C3.cycloalkyl, C 3

_

7 cycloalkenyl,

C

3 -20heterocyclyl, C5.20oaryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino); 30 R c l is H, a C5- 2 0 aryl group, a C 5

.-

2 0 heteroaryl group, a C 1

.

7 alkyl group or NRN 8

RN

9 where RNs and RN 9 are independently selected from H, a CI-7 alkyl group, a C5- 20 heteroaryl group, a

C

5

-

20 aryl group or RNs and RN 9 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, where each CI.

7 alkyl, C5-.

WO 2007/060404 PCT/GB2006/004327 -20 20heteroaryl, C5- 20 aryl or heterocyclic ring is optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or CI_ 7 alkyl, C 2

-

7 alkenyl,

C

2 -7alkynyl, C 3

.

7 cycloalkyl, C 3

.

7 cycloalkenyl, C3-20heterocyclyl, C5-20oaryl, C5-.20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, 5 thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, CI_ 7 alkyl, C 2

.-

7 alkenyl, C 2

.

7 alkynyl,

C

3

.

7 cycloalkyl, C 3

-

7 cycloalkenyl, C 3 .- 20heterocyclyl, C5-20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino); 10 Rs2a is H, a C 5

-

20 aryl group, a C 5

-

20 heteroaryl group, or a CI- 7 alkyl group where each C 1 7 alkyl, Cs5-20heteroaryl or C 5 .- 20ayl is optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or CI.

7 alkyl, C 2

.

7 alkenyl, C 2

-

7 alkynyl,

C

3

.

7 cycloalkyl, C 3

.

7 cycloalkenyl, C 3 -20heterocyclyl, C5-20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and 15 sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, CI.

7 alkyl, C 2 -7alkenyl, C 2

.

7 alkynyl, C 3

-

7 cycloalkyl,

C

3

-

7 cycloalkenyl, C 3 -20heterocyclyl, C5-20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino); 20 RN 7 a and RN7b are H or a C 1

-

4 alkyl group; R" and RN 4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or CI.7alkyl, C 2

-

7 alkenyl, C 2 -7alkynyl,

C

3

.

7 cycloalkyl, C 3

.

7 cycloalkenyl, C 3 -20heterocyclyl, Cs-20aryl, Cs 5 -2o0heteroaryl, ether, acyl, 25 ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, Cl- 7 alkyl, C 2

-

7 alkenyl, C 2 -7alkynyl, C 3

-

7 cycloalkyl,

C

3

.

7 cycloalkenyl, C 3 -20heterocyclyl, Cs-20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and 30 sulfonamino);

R

2 is H, halo, ORO 2 , SRs 2 b, NRN 5

RN

6 , a C 5

-

2 0 heteroaryl group optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or C 1

.

7 alkyl,

C

2 -7alkenyl, C 2

.-

7 alkynyl, C 3

.-

7 cycloalkyl, C 3

.

7 cycloalkenyl, C3-20heterocyclyl, C 5 -20oaryl, WO 2007/060404 PCT/GB2006/004327 -21 C 5 -20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, C 1

-

7 alkyl, C 2 -7alkenyl,

C

2 .- 7alkynyl, C 3

-

7 cycloalkyl, C3- 7 cycloalkenyl, C 3 -20heterocyclyl, C5-20aryl, C5-20heteroaryl, 5 ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino), or a C 5

-

20 aryl group optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or CI.7alkyl,

C

2

.-

7 alkenyl, C 2 .- 7alkynyl, C3- 7 cycloalkyl, C 3

-

7 cycloalkenyl, C 3 -20heterocyclyl, Cs 5 -20aryl,

C

5 -20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, 10 sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, Ci- 7 alkyl, C 2

-

7 alkenyl,

C

2

-

7 alkynyl, C 3 7 cycloalkyl, C 3

-

7 cycloalkenyl, C 3 -20heterocyclyl, C5-20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino), 15 wherein Ro 2 and Rs 2 b are H, a C5- 20 aryl group, a C5- 20 heteroaryl group, or a C 1

.-

7 alkyl group where each C 1

.

7 alkyl, C 5 -20heteroaryl or Cs 5 -20aryl is optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or Ci.

7 alkyl,

C

2

-

7 alkenyl, C 2

-

7 alkynyl, C 3

-

7 cycloalkyl, C 3 .cycloalkenyl, C 3 -20heterocyclyl, C5-20aryl, Cs 5 -20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, 20 sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, C 1

.-

7 alkyl, C 2 -7alkenyl,

C

2

-

7 alkynyl, C 3

-

7 cycloalkyl, C 3

.

7 cycloalkenyl, C 3 -20heterocyclyl, Cs-20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino); 25 RN 5 and RN 6 are independently H, a CI-7 alkyl group, a C 5

-

20 heteroaryl group, a C5-20 aryl group, or RN 5 and RN 6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms where each CI.

7 alkyl, Cs-20heteroaryl, Cs.-20aryl or heterocyclic ring is optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or Ci.7alkyl, C2-7alkenyl, C 2 -7alkynyl, 30 C 3

.

7 cycloalkyl, C 3

.

7 cycloalkenyl, C 3 -20heterocyclyl, Cs 5 .- 20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, Ci.- 7 alkyl, C 2 .- 7alkenyl, C 2 -7alkynyl, C 3

.

7 cycloalkyl, WO 2007/060404 PCT/GB2006/004327 -22 C 3

.

7 cycloalkenyl, C 3 -20heterocyclyl, C5- 20 aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino), or a phanmnaceutically acceptable salt thereof, 5 with the proviso that when R 2 is unsubstituted morpholino, RN 3 and RN 4 together with the nitrogen atom to which they are attached form an unsubstituted morpholino and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not N and X 8 is not CH, or X 6 is not CH and

X

8 is not N, and when R 2 is unsubstituted piperidinyl, R 3 and RN 4 together with the nitrogen atom to which 10 they are attached form an unsubstituted piperidinyl and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not CH and X 8 is not N. According to a further aspect of the present invention there is provided a compound of formula I(A): N4 N3 R N NIO 5 R NH X 5 ' N R R2 I(A) 15 wherein: one or two of X 5 , X 6 and X 8 is N, and the others are CH;

RN

3 and RN 4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or C

I

-

7 alkyl, C 2 -7alkenyl, C 2

-

7 alkynyl, 20 C 3 7 cycloalkyl, C 3

.-

7 cycloalkenyl, C 3 .- 20heterocyclyl, C5-20aryl, C5-20heteroaiyl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, Ci_ 7 alkyl, C 2

-

7 alkenyl, C 2

.

7 alkynyl, C 3

.

7 cycloalkyl,

C

3

.

7 cycloalkenyl, C 3 -20heterocyclyl, C 5 -20aryl, C5-20heteroaryl, ether, acyl, ester, amido, 25 amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino);

R

2 is H, halo, OR 2 , SRS 2 b, NRNSRN 6 ', a C5- 2 0 heteroaryl group optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or C 1

.

7 alkyl, C2- 7 alkenyl, C 2 -7alkynyl, C3-7cycloalkyl, C 3

.

7 cycloalkenyl, C 3 -20heterocyclyl, Cs 5

-

2 zoaryl, WO 2007/060404 PCT/GB2006/004327 - 23 Cs 5 -20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, Ci.- 7 alkyl, C 2 .- 7alkenyl,

C

2

-

7 alkynyl, C3- 7 cycloalkyl, C3-7cycloalkenyl, C3-20heterocyclyl, Cs.20aryl, C5-20heteroaryl, 5 ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino), or C5- 2 0 aryl group optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or CI- 7 alkyl, C 2 -7alkenyl, C2.-7alkynyl, C3.7cycloalkyl, C3- 7 cycloalkenyl, C3-20heterocyclyl, Cs5-20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, 10 thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, CI- 7 alkyl, C 2

-

7 alkenyl, C2.-7alkynyl, C3- 7 cycloalkyl, C3- 7 cycloalkenyl, C3-20heterocyclyl, C5-20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino), 15 wherein Ro 2 and Rs 2 b are H, a C 5

-

20 aryl group, a C 5

-

20 heteroaryl group, or a C 1

.-

7 alkyl group where each Cl-7alkyl, Cs.-20heteroaryl or C5-20aryl is optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or CI- 7 alkyl,

C

2

-

7 alkenyl, C2-7alkynyl, C 3

-

7 cycloalkyl, C3- 7 cycloalkenyl, C 3 -20heterocyclyl, C5-20aryl,

C

5 -20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, 20 sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, CI.

7 alkyl, C 2

-

7 alkenyl, C2- 7 alkynyl, C3.- 7 cycloalkyl, C3- 7 cycloalkenyl, C 3 .- 20heterocyclyl, Cs-20oaryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino); 25 RN 5 and RN 6 are independently H, a Ci- 7 alkyl group, a C 5

-

20 heteroaryl group, a C 5

-

20 aryl group, or RNs 5 and RN 6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms where each Ci.

7 alkyl, C5-20heteroaryl, C5-20aryl or heterocyclic ring is optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or Ci.

7 alkyl, C2.-7alkenyl, C 2 .- 7alkynyl, 30 C3.

7 cycloalkyl, C 3

.

7 cycloalkenyl, C3.-20heterocyclyl, C5-20a1yl, C.5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, C 1

.

7 alkyl, C 2 -7alkenyl, C2.

7 alkynyl, C3.

7 cycloalkyl, WO 2007/060404 PCT/GB2006/004327 - 24 C3.

7 cycloalkenyl, C 3 -20heterocyclyl, C5-20aryl, C5-.

20 heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino);

R

0 3 is hydrogen or a CI- 6 alkyl group optionally substituted by one or more groups selected 5 from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or C 1

.

7 alkyl, C 2 -7alkenyl, C 2 .- 7alkynyl,

C

3

.

7 cycloalkyl, C 3

.

7 cycloalkenyl, C 3 -20heterocyclyl, C5-.20aryl, C 5 -20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, C l-7alkyl, C 2 -7alkenyl, C 2

-

7 alkynyl, C 3

.-

7 cycloalkyl, 10 C 3

.

7 cycloalkenyl, C 3 -20heterocyclyl, Cs.-20aryl, Cs 5 .- 20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino); and RNo is C(=0)R 2 , C(=S)R 3 , SO2R S3 , a C 5

-

20 heteroaryl group optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or CI.7alkyl, 15 C 2

-

7 alkenyl, C 2

-

7 alkynyl, C 3

.-

7 cycloalkyl, C 3

.

7 cycloalkenyl, C 3 -20heterocyclyl, C5-20oaryl,

C

5 -. 20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, Cl.

7 alkyl, C 2

-

7 alkenyl,

C

2

-

7 alkynyl, C 3

.-

7 cycloalkyl, C 3

.

7 cycloalkenyl, C 3 .- 20heterocyclyl, C 5

-

20 aryl, C5- 2 0 heteroaryl, 20 ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino), a C5- 20 aryl group optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or Ci.

7 alkyl, C 2

.-

7 alkenyl,

C

2

.-

7 alkynyl, C 3

.

7 cycloalkyl, C 3

.

7 cycloalkenyl, C 3

.

2 0 heterocyclyl, C5-20oaryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, 25 thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, C.

7 alkyl, C 2

.-

7 alkenyl, C 2

.-

7 alkynyl,

C

3

-

7 cycloalkyl, C 3

.-

7 cycloalkenyl, C 3 -20heterocyclyl, C5-20aryl, C5-.20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino), or a C 1 -io alkyl group optionally substituted by one or more groups selected 30 from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or CI.

7 alkyl, C 2

.-

7 alkenyl, C 2 .- 7alkynyl,

C

3

.

7 cycloalkyl, C 3

.

7 cycloalkenyl, C3- 20 heterocyclyl, Cs5-20aryl, Cs5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, WO 2007/060404 PCT/GB2006/004327 -25 hydroxyl, nitro, cyano, carboxy, thiol, C _ 7 alkyl, C 2 -7alkenyl, C 2

-

7 alkynyl, C 3

-

7 cycloalkyl, C3.

7 cycloalkenyl, C3-20heterocyclyl, Cs.5-20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino), 5 where Rc 2 and RC 3 are H, a C 5

-

20 aryl group, a C5- 20 heteroaryl group, a C.-7 alkyl group or NRNIlRNI 2 , where RN and RN1 2 are independently H, a C 1 .-7 alkyl group, a C 5

-

2 0 heteroaryl group, a C 5

-

20 aryl group or RN 11 and RNI 2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, where each Ci.- 7 alkyl, Cs. 20heteroaryl, Cs.5-20aryl or heterocyclic ring is optionally substituted by one or more groups 10 selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or CI- 7 alkyl, C 2

.-

7 alkenyl,

C

2 .- 7alkynyl, C 3

-

7 cycloalkyl, C 3

.

7 cycloalkenyl, C3.-20heterocyclyl, C5-20aryl, Cs5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, CI- 7 alkyl, C 2

-

7 alkenyl, C 2

.-

7 alkynyl, 15 C3.- 7 cycloalkyl, C3.-7cycloalkenyl, C3.-20heterocyclyl, C5-.20oaryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino), and R s3 is H, a C 5

-

20 aryl group, a C5- 20 heteroaryl group, or a C 1

-

7 alkyl group where each C 1

.-

7 alkyl, Cs.5-20heteroaryl or C5-20aryl is optionally substituted by one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, and thiol, or Ci.

7 alkyl, 20 C 2

-

7 alkenyl, C2.-7alkynyl, C3-7cycloalkyl, C3-7cycloalkenyl, C3-20heterocyclyl, C5-20aryl, C5-20heteroaryl, ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino (each optionally substituted with one or more groups selected from halo, hydroxyl, nitro, cyano, carboxy, thiol, C-.

7 alkyl, C 2

.-

7 alkenyl,

C

2

.-

7 alkynyl, C3.7cycloalkyl, C3-7cycloalkenyl, C3-20heterocyclyl, Cs.5-20aryl, C5-20heteroaryl, 25 ether, acyl, ester, amido, amino, acylamido, ureido, acyloxy, thioether, sulfoxide, sulfonyl, thioamido and sulfonamino), or a pharmaceutically acceptable salt thereof. Further Preferences The following preferences can apply to each aspect of the present invention, where 30 applicable. The preferences for each group may be combined with those for any or all of the other groups, as appropriate.

X

,

X, and X WO 2007/060404 PCT/GB2006/004327 - 26 It is preferred that only one of X 5 , X 6 and X 8 is N. More preferably one of X 5 and X 8 is N, and most preferably X 8 is N.

R

7

R

7 is preferably selected from an optionally substituted C 5

-

20 aryl group, ORol, SRsI, 5 NR IRN 2 , NRN 7 aC(=O)RC1 and NRN 7 bSO 2 Rs 2 a, where Rl 1 , R s1 , RN 1 , RN 2 , RN 7 a, RN 7 b, RCI and Rs 2 a are as previously defined. It is further preferred that R 7 is preferably selected from an optionally substituted C5- 2 0 aryl group, ORo , NRR 2, NRN7aC(o)RcI and NRN7bSO2RS2a If R 7 is a C 5

-

20 aryl group, it is preferably a C5-10o aryl and more preferably C 5 -6 aryl group. Most preferably R 7 is an optionally substituted phenyl group, wherein the optional 10 substituents are preferably selected from halo, hydroxyl, C 1 -7 alkyl and C 1

-

7 alkoxy. In one embodiment, R 7 is an optionally substituted C5- 1 0 aryl group, wherein the optional substituents are selected from cyano, halo, hydroxyl, and C 1

.-

7 alkyl and C 1

.-

7 alkoxy (wherein the alkyl groups may be optionally substituted by one or more groups selected from halo, hydroxyl, Ci.

7 alkoxy, amino and C 5

-

6 aiyl). In another embodiment, R 7 is an optionally 15 substituted C 5

-

6 aryl group, wherein the optional substituents are selected from cyano, halo, hydroxyl, and Ci.-7 alkyl and C 1

.-

7 alkoxy (wherein the alkyl groups may be optionally substituted by one or more groups selected from halo, hydroxyl, C1- 7 alkoxy, amino and C5-6 aryl). In a further embodiment R 7 is a thiophenyl group or a phenyl goup optionally substituted by one or more groups selected from chloro, hydroxyl, methyl, methoxy, ethoxy, 20 i-propoxy, benzyloxy and hydroxymethyl. In a further embodiment R 7 is 4-chlorophenyl, 4 methylphenyl, 4-methoxyphenyl, 3-hydroxymethyl-4-methoxy-phenyl, 3,5-dimethoxy-4 hydroxyphenyl, 4-hydroxyphenyl, 3-hydroxyphenyl or a 3-hydroxymethylphenyl group. In a still further embodiment R 7 is an aryl group as defined in any of examples la, lb, 1 d, le, 1 f, 1g, li, 1k, 11, lm, In, lo, 1p, lq, lbb, Ibc, lbd, lbe, lbf, lbg, lbh, 1bi, lbj or lbr. 25 If R 7 is ORO t , then preferably Rl 1 is a C1- 7 alkyl group, which may be substituted. If R 7 is NRNIRN 2 , then preferably RN 2 is selected from H and C 1

-

4 alkyl (e.g. methyl) and more preferably is H. If RI is C 1

-

7 alkyl, it is preferably selected from C 3

.-

7 cycloalkyl. If R is C5-2 0 aryl, it is preferably selected from Cs- 1 0 aryl and more preferably C 5

-

6 aryl (e.g. phenyl, pyrrolyl, pyridyl, furanyl, thiophenyl, pyrazinyl, pyrimidinyl, thiazolyl, imidazolyl, 30 triazolyl, oxadiazolyl). Particularly preferred groups include phenyl, pyridyl, pyrrolyl and thiophenyl. The aforementioned groups are optionally substituted, and in some embodiments are preferably substituted. Substituent groups may include, but are not limited to, C 1

.

7 alkyl,

C

3 -20heterocyclyl, Cs5-20aryl, carboxy, ester, hydroxy, aryloxy, cyano, halo, nitro, and amino.

WO 2007/060404 PCT/GB2006/004327 - 27 If R 7 is NRN 7 aC(=O)RCl, then RN 7 a is preferably H. R c d may be an optionally substituted C5- 20 aryl group (e.g. phenyl, imadazolyl, quinoxalinyl), C 3

-

20 heterocyclyl, C1-7 alkyl (e.g. propenyl, methyl (substituted with thiophenyl)) or NRN 8

RN

9 . RN 8 ' is preferably hydrogen, and RN 9 is preferably C-7 alkyl (e.g. ethyl). 5 If R7 is NRN 7 bSO 2 Rs 2 a, then RN7b is preferably H. Rs 2 a is preferably C1-i.7 alkyl (e.g. methyl). RNIO RNo is preferably selected from C(=S)Rc 3 , an optionally substituted C 5

-

20 heteroaryl group, an optionally substituted C 5

-

20 aryl group, and an optionally substituted CI- 1 0 alkyl 10 group where R C 3 is as previously defined. If R N1 o is C(=S)Rc 3 , then preferably R c 3 is NR"1R N1 2, where RN" and RNI 2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms. If R

N

"o is a C 5

-

20 heteroaryl group, it is preferably a C 5

-

1 0 heteroaryl group and more 15 preferably C 5 -6 heteroaryl group. Most preferably it is an optionally substituted pyrazole group, wherein the optional substituents are preferably selected from halo, hydroxyl, C1-7 alkyl and C 1 -7 alkoxy. If R Nl o is a C 5

-

20 aryl group, it is preferably a C5- 1 0 aryl and more preferably C 5

.-

6 aryl group. Most preferably it is an optionally substituted phenyl group, wherein the optional 20 substituents are preferably selected from halo, hydroxyl, C 1 .- 7 alkyl and C-7 alkoxy. If Ro is a Ci-o 0 alkyl group, it is preferably a C1- 1 0 alkyl group and more preferably Ci-o 0 alkyl group. Most preferably it is an optionally substituted C1- 6 alkyl group, wherein the optional substituents are preferably selected from halo, hydroxyl, C 1-7 alkyl, ether, for example C 1 .- 7 alkoxy, thioether, for example C 1 -7 alkylthio, C5-.

20 aryl, C 3

-

20 heterocyclyl, C5- 20 25 heteroaryl, cyano, ester, for example -C(=O)OR where R is Cz.

7 alkyl, and amino, for example Ci.

7 alkylamino, di-C_.

7 alkylamino and Cl.

7 alkoxycarbonylamino. In one embodiment RNo is a group as shown in any of examples 8a, 8b, 8c, 8d, 8e, 8f, 8g, 8h, 8i, 8j, 8k, 81, 8m, 8n, 8o, 8t, 8u, 8aa, 8ab, 8ac, 8ad, 8ae, 8af, 8ag, 8ah, 8ai, 8aj, 8ak, 8al, 8am, 8an, 8ao, 8ap, 8aq, 8ar, 8as, 8at, 8au, 8av, 8aw, 8ax, 8ay, 8az, 8ba, 8bb, 8bc, 8bd, 30 8be and 8bg.

R

o 0 3 Ro 3 is preferably an optionally substituted C 1

-

6 alkyl group. More preferably RO 3 is an unsubstituted C 1

-

3 alkyl group, preferably a methyl group.

WO 2007/060404 PCT/GB2006/004327 -28 RN 3 and RN 4

RN

3 and RN 4 together with the nitrogen to which they are bound preferably form a heterocyclic ring containing between 5 and 7 ring atoms, which may optionally be substituted. Preferred optionally substituted groups include, but are not limited, to morpholino, 5 thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) and pyrrolidinyl. More preferably the group formed is morpholino or thiomorpholino, which are preferably unsubstituted. The most preferred group is morpholino.

R

2 10 In one embodiment R 2 is selected from NRNSRN 6 , an optionally substituted C 5

-

20 heteroaryl group, and an optionally substituted C 5

-

20 aryl group. In another embodiment R 2 is selected from NRNSRN 6 , an optionally substituted C 5 -6 heteroaryl group, and an optionally substituted C 6 aryl group. In a further embodiment R 2 is phenyl group optionally substituted with one or more 15 groups selected from hydroxyl, amino, nitro, carboxyl, formyl, cyano, methyl, amido, methyl, methoxymethyl and hydroxymethyl. In a still further embodiment R 2 is an aryl group as shown in any of examples 9a, 9b, 9c, 9d, 9e, 9f, 9g, 9h, 9i, 9j, 9k, 91, 9m, 9n and 9ae. Preferably R 2 is NRNSRN 6 , where RN 5 and RN 6 are as previously defined, and more 20 preferably R N5 and RN 6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, which may optionally be substituted. The ring preferably has from 5 to 7 ring atoms. Preferred optionally substituted groups include, but are not limited, to morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) and pyrrolidinyl. 25 Preferred N-substituents for the piperazinyl and homopiperazinyl groups include esters, in particular, esters bearing a C 1

-

7 alkyl group as an ester substituent, e.g. -C(=O)OCH 3 ,

-C(=O)OCH

2

CH

3 and -C(=O)OC(CH 3

)

3 . Preferred C-substituents for the groups include C1- 4 alkyl, preferably methyl. The groups may bear one or more substituents, for example one or two substituents. 30 More preferred groups are morpholino and piperidinyl. These are preferably substituted with one or two methyl substituents. If these groups bear two methyl substituents, these are preferably on separate carbon atoms. Particularly preferred groups include: WO 2007/060404 PCT/GB2006/004327 -29 I I 0 or %1" or In an embodiment of the invention, there is provided a subset of compounds of formula (I), and pharmaceutically acceptable salts thereof, in which: only one of X 5 , X 6 and X 8 is N; 5 R 7 is selected from an optionally substituted C 5

-

20 aryl group, ORO', NRNlRN 2 ,

NRN

7 aC(=O)RCl and NRN 7 bSO 2

RS

2 a;

R

3 and RN 4 together with the nitrogen to which they are bound form a heterocyclic ring containing between 5 and 7 ring atoms, which may optionally be substituted; and

R

2 is selected from NRNSRN 6 , an optionally substituted C5- 20 heteroaryl group, and an 10 optionally substituted C 5

-

20 aryl group. In another embodiment, there is provided a subset of compounds of formula (I), and pharmaceutically acceptable salts thereof, in which: only one of X 5 , X 6 and X 8 is N; R7 is an optionally substituted C 5

-

6 aryl group, wherein the optional substituents are 15 selected from cyano, halo, hydroxyl, and C1- 7 alkyl and C 1

.-

7 alkoxy (wherein the alkyl groups may be optionally substituted by one or more groups selected from halo, hydroxyl, C1-7 alkoxy, amino and C5.- 6 aryl);

R

N3 and RN 4 together with the nitrogen to which they are bound preferably form an optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl 20 (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group; and

R

2 is selected from NRNSRN 6 , an optionally substituted C5- 6 heteroaryl group, and an optionally substituted C 6 aryl group. In another embodiment, there is provided a subset of compounds of formula (I), and 25 pharmaceutically acceptable salts thereof, in which: only one of X 5 , X 6 and X 8 is N;

R

7 is an optionally substituted C 5 -6 aryl group, wherein the optional substituents are selected from cyano, halo, hydroxyl, and C 1

.-

7 alkyl and C1-7 alkoxy (wherein the alkyl groups may be optionally substituted by one or more groups selected from halo, 30 hydroxyl, C 1

-

7 alkoxy, amino and C 5

-

6 aryl); WO 2007/060404 PCT/GB2006/004327 -30 R M and RN 4 together with the nitrogen to which they are bound preferably form an optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group; and 5 R 2 is NRNSRN 6 where RN 5 and RN 6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 5 to 7 ring atoms which may be optionally be substituted. In a further embodiment, there is provided a subset of compounds of formula (I), and pharmaceutically acceptable salts thereof, in which: 10 only one of X 5 , X 6 and X 8 is N;

R

7 is an optionally substituted C 5

-

6 aryl group, wherein the optional substituents are selected from cyano, halo, hydroxyl, and C 1

-

7 alkyl and C1-7 alkoxy (wherein the alkyl groups may be optionally substituted by one or more groups selected from halo, hydroxyl, C 1 -7, alkoxy, amino and C5-6 aryl); 15 RN 3 and RN 4 together with the nitrogen to which they are bound preferably form an optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group; and

R

2 is NRNSRN 6 where RN 5 and RN 6 together with the nitrogen to which they are bound 20 form an optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group. In a further embodiment, there is provided a subset of compounds of formula (I), and pharmaceutically acceptable salts thereof, in which: 25 X 8 is N;

R

7 is a thiophenyl group or a phenyl goup optionally substituted by one or more groups selected from chloro, hydroxyl, methyl, methoxy, ethoxy, i-propoxy, benzyloxy and hydroxymethyl;

RN

3 and RN 4 together with the nitrogen to which they are bound preferably form an 30 optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group; and WO 2007/060404 PCT/GB2006/004327 -31

R

2 is NRNSRN 6 where RN 5 and RN 6 together with the nitrogen to which they are bound form an optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group. 5 In a further embodiment, there is provided a subset of compounds of formula (I), and pharmaceutically acceptable salts thereof, in which:

X

8 is N; R7 is a thiophenyl group or a phenyl goup optionally substituted by one or more groups selected from chloro, hydroxyl, methyl, methoxy, ethoxy, i-propoxy, 10 benzyloxy and hydroxymethyl;

RN

3 and RN 4 together with the nitrogen to which they are bound preferably form an optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group; and 15 R2 is NRNSRN 6 where RNs and RN 6 together with the nitrogen to which they are bound form a morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group optionally substituted on carbon with one or more Ci- 4 alkyl groups. In a further embodiment, there is provided a subset of compounds of formula (I), and 20 pharmaceutically acceptable salts thereof, in which:

X

8 is N;

R

7 is a thiophenyl group or a phenyl goup optionally substituted by one or more groups selected from chloro, hydroxyl, methyl, methoxy, ethoxy, i-propoxy, benzyloxy and hydroxymethyl; 25 R N 3 and RN 4 together with the nitrogen to which they are bound preferably form a morpholino or thiomorpholino; and

R

2 is NRNSRN 6 where RN' and RN 6 together with the nitrogen to which they are bound form a morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group 30 optionally substituted on carbon with one or more Ci- 4 alkyl groups. In a further embodiment, there is provided a subset of compounds of formula (I), and pharmaceutically acceptable salts thereof, in which:

X

8 is N; WO 2007/060404 PCT/GB2006/004327 - 32 R 7 is a 4-chlorophenyl, 4-methylphenyl, 4-methoxyphenyl, 3-hydroxymethyl-4 methoxy-phenyl, 3,5-dimethoxy-4-hydroxyphenyl, 4-hydroxyphenyl, 3 hydroxyphenyl or a 3-hydroxymethylphenyl group;

RN

3 and RN 4 together with the nitrogen to which they are bound preferably form a 5 morpholino or thiomorpholino; and

R

2 is NRNSRN 6 where RN 5 and RN 6 together with the nitrogen to which they are bound ~, N N , N Olii or "'LIOhI ", or form a or or group. In a further embodiment, there is provided a subset of compounds of formula (I), and pharmaceutically acceptable salts thereof, in which: 10 X 8 is N;

R

7 is a 4-chlorophenyl, 4-methylphenyl, 4-methoxyphenyl, 3-hydroxymethyl-4 methoxy-phenyl, 3,5-dimethoxy-4-hydroxyphenyl, 4-hydroxyphenyl, 3 hydroxyphenyl or a 3-hydroxymethylphenyl group;

R

N3 and RN 4 together with the nitrogen to which they are bound preferably form an 15 unsubstituted morpholino; and

R

2 is NRNSRN 6 where R R and R 6 together with the nitrogen to which they are bound *€ * N ~ N N formO or "'h O ", or form a 0 or or group. In an embodiment of the invention, there is provided a subset of compounds of formula I(A), and pharmaceutically acceptable salts thereof, in which: 20 only one of X 5 , X 6 and X 8 is N; RNo is selected from C(=S)Rc 3 , an optionally substituted C 5

-

20 heteroaryl group, an optionally substituted C 5

-

20 aryl group, and an optionally substituted Cl-O 10 alkyl group where Rc 3 is as previously defined;

R

0 3 is an optionally substituted C 1 .- 6 alkyl group; 25 RN 3 and RN 4 together with the nitrogen to which they are bound form a heterocyclic ring containing between 5 and 7 ring atoms, which may optionally be substituted; and

R

2 is selected from NNSRN 6 , an optionally substituted C 5

-

20 heteroaryl group, and an optionally substituted C5- 20 aryl group.

WO 2007/060404 PCT/GB2006/004327 - 33 In another embodiment, there is provided a subset of compounds of formula I(A), and pharmaceutically acceptable salts thereof, in which: only one of X 5 , X 6 and X 8 is N;

RN

1 o is C(=S)Rc 3 , an optionally substituted C 5

-

6 heteroaryl group, an optionally 5 substituted C 5

-

6 aryl group or an optionally substituted Ci- 1 0 alkyl group where RC 3 is NRlRNI2 and where RN l and RNI 2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms;.

RO

3 is an unsubstituted C 1

-

3 alkyl group;

RN

3 and RN 4 together with the nitrogen to which they are bound preferably form an 10 optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group; and

R

2 is selected from NRNSRN 6 , an optionally substituted C 5

-

6 heteroaryl group, and an optionally substituted C 6 aryl group. 15 In another embodiment, there is provided a subset of compounds of formula I(A), and pharmaceutically acceptable salts thereof, in which: only one of X 5 , X 6 and X 8 is N;

RN

1 o is a C(=S)NR"RNI 2 group where RN l 1 and RN1 2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, 20 or a pyrazole group optionally substituted with one or more groups selected from halo, hydroxyl, C 1 -7 alkyl and C 1

-

7 alkoxy, or a phenyl group optionally substituted with one or more groups selected from halo, hydroxyl, C1-7 alkyl and C1- 7 alkoxy, or a C 1

-

6 alkyl group optionally substituted with one or more groups selected from halo, hydroxyl, C.

7 alkyl, ether, for example C1- 7 alkoxy, thioether, for example C-7 alkylthio, C 5

-

20 aryl, 25 C 3

-

20 heterocyclyl, C 5

-

20 heteroaryl, cyano, ester, for example -C(=O)OR where R is Ci.- 7 alkyl, and amino, for example CI- 7 alkylamino, di-Ci.

7 alkylamino and

CI.

7 alkoxycarbonylamino; Ro 3 is a methyl group;

RN

3 and RN 4 together with the nitrogen to which they are bound preferably form an 30 optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group; and WO 2007/060404 PCT/GB2006/004327 -34

R

2 is NRNSRN 6 where RN' and RN 6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 5 to 7 ring atoms which may be optionally be substituted. In a further embodiment, there is provided a subset of compounds of formula I(A), 5 and pharmaceutically acceptable salts thereof, in which: only one of X 5 , X 6 and X 8 is N; R is a C(=S)NRNiR NI2 group where RN t 11 and RN1 2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, or a pyrazole group optionally substituted with one or more groups selected from halo, 10 hydroxyl, C 1 -7 alkyl and Ci-7 alkoxy, or a phenyl group optionally substituted with one or more groups selected from halo, hydroxyl, C 1 i-7 alkyl and C 1 -7 alkoxy, or a C1- 6 alkyl group optionally substituted with one or more groups selected from halo, hydroxyl, Cj. 7 alkyl, ether, for example C 1

.

7 alkoxy, thioether, for example C1- 7 alkylthio, C 5

-

20 aryl,

C

3

-

20 heterocyclyl, C 5

-

20 heteroaryl, cyano, ester, for example -C(=O)OR where R is 15 Ci.

7 alkyl, and amino, for example C- 1

.

7 alkylamino, di-Cl-7alkylamino and

CI.-

7 alkoxycarbonylamino;

R

3 is a methyl group;

R

3 and RN 4 together with the nitrogen to which they are bound preferably form an optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl 20 (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group; and

R

2 is NRN5sRN 6 where RNs and RN 6 together with the nitrogen to which they are bound form an optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl 25 group. In a further embodiment, there is provided a subset of compounds of formula I(A), and pharmaceutically acceptable salts thereof, in which:

X

8 is N;

R

N i is a C(=S)NRN"RNI 2 group where RN" and RN 1 2 together with the nitrogen to 30 which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, or a pyrazole group optionally substituted with one or more groups selected from halo, hydroxyl, C.1- 7 alkyl and C 1 -7 alkoxy, or a phenyl group optionally substituted with one or more groups selected from halo, hydroxyl, C 1

.

7 alkyl and C.

7 alkoxy, or a Ci.-6 alkyl WO 2007/060404 PCT/GB2006/004327 - 35 group optionally substituted with one or more groups selected from halo, hydroxyl, C 1 I 7 alkyl, ether, for example C 1

.-

7 alkoxy, thioether, for example C 1

.-

7 alkylthio, C5- 20 aryl,

C

3

-

20 heterocyclyl, C 5

-

20 heteroaryl, cyano, ester, for example -C(=O)OR where R is Ci.

7 alkyl, and amino, for example Ci.- 7 alkylamino, di-C 1

.-

7 alkylamino and 5 C I7alkoxycarbonylamino; Ro 3 is a methyl group;

RN

3 and RN 4 together with the nitrogen to which they are bound preferably form an optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl 10 group; and

R

2 is NRNSRN 6 where R 5 and R N6 together with the nitrogen to which they are bound form an optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), homopiperazinyl (preferably N-substituted) or pyrrolidinyl group. 15 In a further embodiment, there is provided a subset of compounds of formula I(A), and pharmaceutically acceptable salts thereof, in which:

X

8 is N;

RN

l o is a C(=S)NRNIlRN1 2 group where RN 11 and RN1 2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, 20 or a pyrazole group optionally substituted with one or more groups selected from halo, hydroxyl, C 1 -7 alkyl and C 1

-

7 alkoxy, or a phenyl group optionally substituted with one or more groups selected from halo, hydroxyl, C 1

.-

7 alkyl and C 1

-

7 alkoxy, or a C1- 6 alkyl group optionally substituted with one or more groups selected from halo, hydroxyl, C 1 . 7 alkyl, ether, for example C1- 7 alkoxy, thioether, for example C.-7 alkylthio, C5- 20 aryl, 25 C 3

-

2 0 heterocyclyl, C 5

-

20 heteroaryl, cyano, ester, for example -C(=O)OR where R is Ci.

7 alkyl, and amino, for example CI.

7 alkylamino, di-CI.-7alkylamino and CI-.7alkoxycarbonylamino;

RO

3 is a methyl group;

RN

3 and RN 4 together with the nitrogen to which they are bound preferably form a 30 morpholino or thiomorpholino group; and

R

2 is NRNSRN 6 where RN' and RN 6 together with the nitrogen to which they are bound form morpholino, thiomorpholino, piperidinyl, piperazinyl (preferably N-substituted), WO 2007/060404 PCT/GB2006/004327 - 36 homopiperazinyl (preferably N-substituted) or pyrrolidinyl group optionally substituted on carbon by one or more C 1

-

4 alkyl groups. In a further embodiment, there is provided a subset of compounds of formula I(A), and pharmaceutically acceptable salts thereof, in which: 5 X 8 is N; RNo is a C(=S)NRNlRNI 2 group where R" and RN12 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, or a pyrazole group optionally substituted with one or more groups selected from halo, hydroxyl, C 1

.-

7 alkyl and C 1

-.

7 alkoxy, or a phenyl group optionally substituted with one 10 or more groups selected from halo, hydroxyl, C1- 7 alkyl and C1- 7 alkoxy, or a Cl- 6 alkyl group optionally substituted with one or more groups selected from halo, hydroxyl, C 1 . 7 alkyl, ether, for example C 1

-

7 alkoxy, thioether, for example C 1

-

7 alkylthio, C5- 20 aryl,

C

3

-

20 heterocyclyl, C 5

-

20 heteroaryl, cyano, ester, for example -C(=O)OR where R is Ci.7alkyl, and amino, for example Ci.

7 alkylamino, di-Ci.

7 alkylamino and 15 Cl-7alkoxycarbonylamino;

R

0 3 is a methyl group;

RN

3 and RN 4 together with the nitrogen to which they are bound preferably form a morpholino or thiomorpholino group; and

R

2 is NRNSRN 6 where RN' and RN 6 together with the nitrogen to which they are bound N N N O or "' ' or 20 form a or " group. group. In a further embodiment, there is provided a subset of compounds of formula I(A), and pharmaceutically acceptable salts thereof, in which:

X

8 is N;

RN

1 o is a C(=S)NRN RNI 2 group where R 1 1 and RNI 2 together with the nitrogen to 25 which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, or a pyrazole group optionally substituted with one or more groups selected from halo, hydroxyl, C 1 -7 alkyl and C1-7 alkoxy, or a phenyl group optionally substituted with one or more groups selected from halo, hydroxyl, C1- 7 alkyl and C 1

.-

7 alkoxy, or a C1-6 alkyl group optionally substituted with one or more groups selected from halo, hydroxyl, C. 30 7 alkyl, ether, for example Ci.-7 alkoxy, thioether, for example C.- 7 alkylthio, C 5

-

20 aryl,

C

3

-

20 heterocyclyl, C 5

-

20 heteroaryl, cyano, ester, for example -C(=O)OR where R is WO 2007/060404 PCT/GB2006/004327 -37 C .

7 alkyl, and amino, for example Cl7alkylamino, di-Ci- 7 alkylamino and CI-7alkoxycarbonylamino;

R

0 3 is a methyl group;

RN

3 and RN 4 together with the nitrogen to which they are bound preferably form an 5 unsubstituted morpholino group; and

R

2 is NRNsRN 6 where RN 5 ' and RN 6 together with the nitrogen to which they are bound I '~ N N N f or o or ," o ' or form a group. In another aspect of the invention, particular compounds of the invention are any one of the Examples or pharmaceutically acceptable salts thereof. 10 In a further aspect of the invention, particular compounds of the invention are any one of Examples la, lb, ld, le, lf, lg, li, 1k, 11, lm, In, lo, lp, lq, lbb, lbc, lbd, lbe, lbf, lbg, lbh, lbi, lbj, lbr, 8a, 8b, 8c, 8d, 8e, 8f, 8g, 8h, 8i, 8j, 8k, 81, 8m, 8n, 80, 8t, 8u, 8aa, 8ab, 8ac, 8ad, 8ae, 8af, 8ag, 8ah, 8ai, 8aj, 8ak, 8al, 8am, 8an, 8ao, 8ap, 8aq, 8ar, 8as, 8at, 8au, 8av, 8aw, 8ax, 8ay, 8az, 8ba, 8bb, 8bc, 8bd, 8be, 8bg, 9a, 9b, 9c, 9d, 9e, 9f, 9g, 9h, 9i, 9j, 9k, 91, 9m, 9n 15 and 9ae, or pharmaceutically acceptable salts thereof. Includes Other Forms Included in the above are the well known isomers, ionic, salt, solvate, protected forms and prodrugs of these compounds and substituents. For example, a reference to carboxylic acid (-COOH) also includes the anionic (carboxylate) form (-COO), a salt or solvate thereof, 20 as well as conventional protected forms. Similarly, a reference to an amino group includes the protonated form (-NHR'R 2 ), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected forms of an amino group. Similarly, a reference to a hydroxyl group also includes the anionic form (-O'), a salt or solvate thereof, as well as conventional protected forms of a hydroxyl group. 25 Isomers, Salts, Solvates, Protected Forms, and Prodrugs Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diasteriomeric, epimeric, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r-forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and 1-forms; (+) 30 and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal forms; a- and P3-forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and WO 2007/060404 PCT/GB2006/004327 -38 halfchair-forms; and combinations thereof, hereinafter collectively referred to as "isomers" (or "isomeric forms"). If the compound is in crystalline form, it may exist in a number of different polymorphic forms. 5 Note that, except as discussed below for tautomeric forms, specifically excluded from the term "isomers", as used herein, are structural (or constitutional) isomers (i.e. isomers which differ in the connections between atoms rather than merely by the position of atoms in space). For example, a reference to a methoxy group, -OCH 3 , is not to be construed as a reference to its structural isomer, a hydroxymethyl group, -CH20H. Similarly, a reference to 10 ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta chlorophenyl. However, a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g., C1-7 alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para methoxyphenyl). 15 The above exclusion does not pertain to tautomeric forms, for example, keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol, imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N nitroso/hyroxyazo, and nitro/aci-nitro. Note that specifically included in the term "isomer" are compounds with one or more 20 isotopic substitutions. For example, H may be in any isotopic form, including 'H, 2 H (D), and 3 H (T); C may be in any isotopic form, including 12 C, 1 3 C, and 1 4 C; O may be in any isotopic form, including 160 and 180; and the like. Unless otherwise specified, a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof. Methods 25 for the preparation (e.g. asymmetric synthesis) and separation (e.g. fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner. Unless otherwise specified, a reference to a particular compound also includes ionic, salt, solvate, and protected forms of thereof, for example, as discussed below, as well as its 30 different polymorphic forms. It may be convenient or desirable to prepare, purify, and/or handle a corresponding salt of the active compound, for example, a pharmaceutically-acceptable salt. Examples of pharmaceutically acceptable salts are discussed in ref. 25.

WO 2007/060404 PCT/GB2006/004327 - 39 For example, if the compound is anionic, or has a functional group which may be anionic (e.g., -COOH may be -COO-), then a salt may be formed with a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K , alkaline earth cations such as Ca 2+ and Mg 2+ , and other cations such as Al1 3 . 5 Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e.,

NH

4

+

) and substituted ammonium ions (e.g., NH 3

R

+

, NH 2

R

2 , NHR 3 , NR 4 ). Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and 10 tromethamine, as well as amino acids, such as lysine and arginine. An example of a common quaternary ammonium ion is N(CH 3

)

4 +. If the compound is cationic, or has a functional group which may be cationic (e.g.,

-NH

2 may be -NH 3 +), then a salt may be formed with a suitable anion. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic 15 acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous. Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: acetic, propionic, succinic, gycolic, stearic, palmitic, lactic, malic, pamoic, tartaric, citric, gluconic, ascorbic, maleic, hydroxymaleic, phenylacetic, glutamic, aspartic, benzoic, cinnamic, pyruvic, salicyclic, sulfanilic, 20 2-acetyoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethanesulfonic, ethane disulfonic, oxalic, isethionic, valeric, and gluconic. Examples of suitable polymeric anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose. It may be convenient or desirable to prepare, purify, and/or handle a corresponding 25 solvate of the active compound. The term "solvate" is used herein in the conventional sense to refer to a complex of solute (e.g. active compound, salt of active compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc. It may be convenient or desirable to prepare, purify, and/or handle the active 30 compound in a chemically protected form. The term "chemically protected form," as used herein, pertains to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions, that is, are in the form of a protected or protecting group (also known as a masked or masking group or a blocked or blocking group). By protecting a WO 2007/060404 PCT/GB2006/004327 - 40 reactive functional group, reactions involving other unprotected reactive functional groups can be performed, without affecting the protected group; the protecting group may be removed, usually in a subsequent step, without substantially affecting the remainder of the molecule. See, for example, ref. 26. 5 For example, a hydroxy group may be protected as an ether (-OR) or an ester (-OC(=O)R), for example, as: a t-butyl ether; a benzyl, benzhydryl (diphenylmethyl), or trityl (triphenylmethyl) ether; a trimethylsilyl or t-butyldimethylsilyl ether; or an acetyl ester

(-OC(=O)CH

3 , -OAc). For example, an aldehyde or ketone group may be protected as an acetal or ketal, 10 respectively, in which the carbonyl group (>C=O) is converted to a diether (>C(OR) 2 ), by reaction with, for example, a primary alcohol. The aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid. For example, an amine group may be protected, for example, as an amide or a urethane, for example, as: a methyl amide (-NHCO-CH 3 ); a benzyloxy amide (-NHCO 15 OCH 2

C

6 Hs, -NH-Cbz); as a t-butoxy amide (-NHCO-OC(CH 3

)

3 , -NH-Boc); a 2-biphenyl-2 propoxy amide (-NHCO-OC(CH 3

)

2

C

6

H

4

C

6 Hs, -NH-Bpoc), as a 9-fluorenylmethoxy amide ( NH-Fmoc), as a 6-nitroveratryloxy amide (-NH-Nvoc), as a 2-trimethylsilylethyloxy amide ( NH-Teoc), as a 2,2,2-trichloroethyloxy amide (-NH-Troc), as an allyloxy amide (-NH-Alloc), as a 2(-phenylsulphonyl)ethyloxy amide (-NH-Psec); or, in suitable cases, as an N-oxide 20 (>NO.). For example, a carboxylic acid group may be protected as an ester for example, as: an

C

1 -7 alkyl ester (e.g. a methyl ester; a t-butyl ester); a C1-7 haloalkyl ester (e.g. a C 1 .- 7 trihaloalkyl ester); a triCI.

7 alkylsilyl-C1.

7 alkyl ester; or a C5- 20 aryl-C 1

-

7 alkyl ester (e.g. a benzyl ester; a nitrobenzyl ester); or as an amide, for example, as a methyl amide. 25 For example, a thiol group may be protected as a thioether (-SR), for example, as: a benzyl thioether; an acetamidomethyl ether (-S-CH 2

NHC(=O)CH

3 ). It may be convenient or desirable to prepare, purify, and/or handle the active compound in the form of a prodrug. The term "prodrug", as used herein, pertains to a compound which, when metabolised (e.g. in vivo), yields the desired active compound. 30 Typically, the prodrug is inactive, or less active than the active compound, but may provide advantageous handling, administration, or metabolic properties. For example, some prodrugs are esters of the active compound (e.g. a physiologically acceptable metabolically labile ester). During metabolism, the ester group (-C(=O)OR) is WO 2007/060404 PCT/GB2006/004327 - 41 cleaved to yield the active drug. Such esters may be formed by esterification, for example, of any of the carboxylic acid groups (-C(=0)OH) in the parent compound, with, where appropriate, prior protection of any other reactive groups present in the parent compound, followed by deprotection if required. Examples of such metabolically labile esters include 5 those wherein R is CI- 20 alkyl (e.g. -Me, -Et); Cl-7 aminoalkyl (e.g. aminoethyl; 2-(N,N diethylamino)ethyl; 2-(4-morpholino)ethyl); and acyloxy-CI-7 alkyl (e.g. acyloxymethyl; acyloxyethyl; e.g. pivaloyloxymethyl; acetoxymethyl; 1-acetoxyethyl; 1-(1-methoxy-1 methyl)ethyl-carbonxyloxyethyl; 1-(benzoyloxy)ethyl; isopropoxy-carbonyloxymethyl; 1 -isopropoxy-carbonyloxyethyl; cyclohexyl-carbonyloxymethyl; 1 -cyclohexyl 10 carbonyloxyethyl; cyclohexyloxy-carbonyloxymethyl; 1-cyclohexyloxy-carbonyloxyethyl; (4 tetrahydropyranyloxy) carbonyloxymethyl; 1-(4-tetrahydropyranyloxy)carbonyloxyethyl; (4 tetrahydropyranyl)carbonyloxymethyl; and 1-(4-tetrahydropyranyl)carbonyloxyethyl). Further suitable prodrug forms include phosphonate and glycolate salts. In particular, hydroxy groups (-OH), can be made into phosphonate prodrugs by reaction with 15 chlorodibenzylphosphite, followed by hydrogenation, to form a phosphonate group -0

P(=O)(OH)

2 . Such a group can be cleared by phosphotase enzymes during metabolism to yield the active drug with the hydroxy group. Also, some prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound. For example, 20 the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative. Acronyms For convenience, many chemical moieties are represented using well known abbreviations, including but not limited to, methyl (Me), ethyl (Et), n-propyl (nPr), iso-propyl 25 (iPr), n-butyl (nBu), tert-butyl (tBu), n-hexyl (nHex), cyclohexyl (cHex), phenyl (Ph), biphenyl (biPh), benzyl (Bn), naphthyl (naph), methoxy (MeO), ethoxy (EtO), benzoyl (Bz), and acetyl (Ac). For convenience, many chemical compounds are represented using well known abbreviations, including but not limited to, methanol (MeOH), ethanol (EtOH), iso-propanol 30 (i-PrOH), methyl ethyl ketone (MEK), ether or diethyl ether (Et 2 O), acetic acid (AcOH), dichloromethane (methylene chloride, DCM), trifluoroacetic acid (TFA), dimethylformamide (DMF), tetrahydrofuran (THF), and dimethylsulfoxide (DMSO). General Synthesis WO 2007/060404 PCT/GB2006/004327 -42 Compounds of formula I can be represented by Formula 1:

R

4 5 X ' - N Formula 1 R z

X

a N R wherein R 4 represents NRN 3

RN

4 . Compounds of Formula 1 can be synthesised from compounds of Formula 2: R4 X5

X

6 X C2 Formula 2 2 5 CI X 8 N R When R 7 is NRNIR , this is by reaction with R 7 H. When R is an optionally substituted C3- 20 heterocyclyl group or C 5

-

20 aryl group, this is by reaction with R 7 B(OAlk) 2 , where each Alk is independently CI- 7 alkyl or together with the oxygen to which they are attached form a C5- 7 heterocyclyl group. When R 7 is an amide, urea or sulfonamide group, 10 this is by reaction with ammonia followed by reaction of the resulting primary amide with the appropriate acid chloride, isocyanate or sulfonyl chloride. When R 7 is ORo 1 or SR s t, this is by reaction with potassium carbonate in the appropriate alcohol or thiol solvent. Therefore, according to a further aspect of the present invention there is provided a process for the preparation of a compound of formula 1, from a compound of Formula 2: R' 5 X \ "N Formula 2 8 2 15 CI X N R wherein:

R

4 is NRN 3

RN

4 where RN 3 and RN 4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms;

R

2 is selected from H, halo, OR 0 2 , SR s b, NR5RN6 , an optionally substituted C 5

-

20 heteroaryl 20 group, and an optionally substituted C5- 20 aryl group, wherein R 0 2 and RS 2 b are selected from H, an optionally substituted C 5

-

20 aryl group, an optionally substituted C5-.

20 heteroaryl group, or an optionally substituted C.- 7 alkyl group, and RNs and RN 6 are independently selected from H, an optionally substituted CI.7 alkyl group, an optionally substituted C5- 20 heteroaryl group, and an optionally substituted Cs- 20 aryl group, or WO 2007/060404 PCT/GB2006/004327 - 43 RN 5 and RN 6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, comprising (a) when R 7 is NRNIRN 2 , reaction of the compound of formula 2 with R7H; or 5 (b) when R 7 is an optionally substituted C3-2 0 heterocyclyl group or C5-2 0 aryl group, reaction of the compound of formula 2 with R 7 B(OAlk) 2 , where each Alk is independently CI- 7 alkyl or together with the oxygen to which they are attached form a

C

5 -7 heterocyclyl group, or (c) when R 7 is an amide, urea or sulfonamide group, reaction of a compound of formula 2 10 with ammonia followed by reaction of the resulting primary amine with the appropriate acid chloride, isocyanate or sulfonyl chloride, or (d) when R 7 is ORO l or SR s t, by reaction of the compound of formula 1 in the presence of base in the appropriate alcohol or thiol solvent. Compounds of formula I(A) can be synthesised by reaction a compound of Formula 15 la:

R

4 R R Formula la R 7, X 8 N 5 R wherein R 4 represents NRN 3

RN

4 , and Lv 03 R°\

R

7 is O , wherein Lv is a leaving group, such as a halogen, for example chlorine, or an OSO 2 R group, where R is alkyl or aryl, such as methyl, 20 by reaction with RNIoNH2. Compounds of Formula 1 a can be synthesised by reaction of a compound of Formula lb R4 6 X R- N 2 Formula la wherein R 4 represents NR RN4, and wherein W 4 represents NR N 3

R

4 , and WO 2007/060404 PCT/GB2006/004327 - 44 OH 03 R /

R

7 is with an alkyl or aryl sulphonyl chloride in the presence of a base. Compounds of Formula lb can be synthesised by reacting a compound of Formula 2:

R

4 5 ( ' 2. Formula 2 Cl X N R 5 with R 7 B(OAlk) 2 , where each Alk is independently C1- 7 alkyl or together with the oxygen to which they are attached form a C5-7 heterocyclyl group. Compounds of Formula 2 can be synthesised from compounds of Formula 3: Cl 5 -X X 'N 1 N Formula3 Cl Xe N CI by reaction with HR 4

(HNRN

3

RN

4 ) followed by reaction with HR 2 . 10 Compounds of Formula 3 can be synthesised from compounds of Formula 4: O 5 X '- NH C X) NH O Formula 4 CI X 8 N 0 H by treatment with POC1 3 and N,N-diisopropylamine, for example. Compounds of Formula 4 can be synthesised from compounds of Formula 5: O 5 X A 5 NIEL X' \ NH 2 I - 2 Formula 5 Cl Xe NH 2 15 by treatment with oxalyl chloride, for example. Compounds of Formula 5 can be synthesised from compounds of Formula 6, for example by reaction with liquid ammonia followed by reaction with thionyl chloride and ammonia gas: WO 2007/060404 PCT/GB2006/004327 - 45 0 O X, OH Cl 8

C

I Formula 6 CIC Alternatively, Compounds of Formula 1 can be synthesised from compounds of Formula 2A: R4 5 X N Formula 2A R 7 X 8 N Cl I 5 When R 2 is NRNSRN 6 , this is by reaction with R 2 H. When R 2 is an optionally substituted C 3

-

20 heterocyclyl group or C 5

-

20 aryl group, this is by reaction with R2B(OAlk) 2 , where each Alk is independently Cl- 7 alkyl or together with the oxygen to which they are attached form a C5-.

7 heterocyclyl group. When R 2 is ORO 2 or SRs 2 b, this is by reaction with potassium carbonate in the appropriate alcohol or thiol solvent. 10 Therefore, according to a further aspect of the present invention there is provided a process for the preparation of a compound of formula 1 from a compound of formula 2A: R 4 5 X V\ " N 7 ' 8 N Formula 2A R X N C I wherein

R

4 is NRN3RN 4 where RN 3 and RN 4 , together with the nitrogen to which they are bound, form a 15 heterocyclic ring containing between 3 and 8 ring atoms; and

R

7 is selected from halo, ORO 1 , SR s ', NRNIRN 2 , NRN 7 aC(=O)RcL, NRN 7 bSO 2 Rs 2 a, an optionally substituted C 5

-

20 heteroaryl group, or an optionally substituted C5- 20 aryl group, where Ro 1 and R s t are selected from H, an optionally substituted C 5

-

20 aryl group, an optionally substituted C5- 20 heteroaryl group, or an optionally substituted C.l- 7 alkyl group; RN' 20 and RN 2 are independently selected from H, an optionally substituted Cl- 7 alkyl group, an optionally substituted C5- 20 heteroaryl group, an optionally substituted C5- 20 aryl group or RNI and RN 2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms;

R

cl is selected from H, an optionally substituted C 5

-

20 aryl group, an optionally substituted C5-. 25 2 0 heteroaryl group, an optionally substituted C.- 7 alkyl group or NRN 8

RN

9 , where RN 8 and RN 9 WO 2007/060404 PCT/GB2006/004327 - 46 are independently selected from H, an optionally substituted Ci-.

7 alkyl group, an optionally substituted C5- 20 heteroaryl group, an optionally substituted C5- 20 aryl group or RN 8 and RN 9 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; 5 R s2a is selected from H, an optionally substituted C 5

-

20 aryl group, an optionally substituted

C

5

-

20 heteroaryl group, or an optionally substituted C 1

-

7 alkyl group; and

R

N

7 a and RN 7 b are selected from H and a C 1

-

4 alkyl group; comprising (a) when R 2 is NRNSRN 6 , reacting a compound of formula 2A with R 2 H, or 10 (b) when R 2 is an opionally substituted C 3

-

20 heterocyclyl group or C 5

-

20 aryl group, by reacting a compound of formula 2A with R 2 B(OAlk) 2 , where each Alk is independently CI-7 alkyl or together with the oxygen to which they are attached form a

C

5

-

7 heterocyclyl group, or (c) when R 2 is OR02 or SRs 2 b, by reacting a compound of formula 2A in the presence of a 15 base in the appropriate alcohol or thiol solvent. Compounds of Formula 2A can be synthesised from compounds of Formula 3: Cl 5 X 5 N Formula 3 Cl X N Cl by reaction with HR 4

(HNRN

3

RN

4 ) followed by reaction with HR 7 or HR 7 equivalent. For example, when R 7 is an optionally substituted C 3

-

20 heterocyclyl group or C5- 20 aryl group, this 20 is by reaction with R 7 B(OAlk) 2 , where each Alk is independently Ct.-7 alkyl or together with the oxygen to which they are attached form a Cs.5-7 heterocyclyl group. Use The present invention provides active compounds, specifically, active in inhibiting the 25 activity of mTOR. The term "active" as used herein, pertains to compounds which are capable of inhibiting mTOR activity, and specifically includes both compounds with intrinsic activity (drugs) as well as prodrugs of such compounds, which prodrugs may themselves exhibit little or no intrinsic activity. 30 One assay which may conveniently be used in order to assess the mTOR inhibition offered by a particular compound is described in the examples below.

WO 2007/060404 PCT/GB2006/004327 - 47 The present invention further provides a method of inhibiting the activity of mTOR in a cell, comprising contacting said cell with an effective amount of an active compound, preferably in the form of a pharmaceutically acceptable composition. Such a method may be practised in vitro or in vivo. 5 For example, a sample of cells may be grown in vitro and an active compound brought into contact with said cells, and the effect of the compound on those cells observed. As examples of "effect", the inhibition of cellular growth in a certain time or the accumulation of cells in the G1 phase of the cell cycle over a certain time may be determined. Where the active compound is found to exert an influence on the cells, this may be used as a prognostic 10 or diagnostic marker of the efficacy of the compound in methods of treating a patient carrying cells of the same cellular type. The term "treatment", as used herein in the context of treating a condition, pertains generally to treatment and therapy, whether of a human or an animal (e.g. in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition 15 of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, amelioration of the condition, and cure of the condition. Treatment as a prophylactic measure (i.e. prophylaxis) is also included. The term "adjunct" as used herein relates to the use of active compounds in conjunction with known therapeutic means. Such means include cytotoxic regimes of drugs 20 and/or ionising radiation as used in the treatment of different cancer types. Examples of adjunct anti-cancer agents that could be combined with compounds from the invention include, but are not limited to, the following: alkylating agents: nitrogen mustards, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil: Nitrosoureas: carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU), 25 ethylenimine/methylmelamine, thriethylenemelamine (TEM), triethylene thiophosphoramide (thiotepa), hexamethylmelamine (HMM, altretamine): Alkyl sufonates; busulfan; Triazines, dacarbazine (DTIC): Antimetabolites; folic acid analogs, methotrexate, trimetrexate, pyrimidine analogs, 5-fluorouracil, fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-azacytidine, 2,2'-difluorodeoxycytidine: Purine analogs; 6 30 mercaptopurine, 6-thioguanine, azathioprine, 2'-deoxycoformycin (pentostatin, eiythrohydroxynonyladenine (EHNA), fludarabine phosphate, 2-Chlorodeoxyadenosine (cladribine, 2-CdA): Topoisomerase I inhibitors; camptothecin, topotecan, irinotecan, rubitecan: Natural products; antimitotic drugs, paclitaxel, vinca alkaloids, vinblastine (VLB), WO 2007/060404 PCT/GB2006/004327 -48 vincristine, vinorelbine, TaxotereTM (docetaxel), estramustine, estramustine phosphate; epipodophylotoxins, etoposide, teniposide: Antibiotics; actimomycin D, daunomycin (rubidomycin), doxorubicin (adriamycin), mitoxantrone, idarubicin, bleomycins, plicamycin (mithramycin), mitomycin C, dactinomycin: Enzymes; L-asparaginase, RNAse A: Biological 5 response modifiers; interferon-alpha, IL-2, G-CSF, GM-CSF: Differentiation Agents; retinoic acid derivatives: Radiosensitizers;, metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, RSU 1069, EO9, RB 6145, SR4233, nicotinamide, 5 bromodeozyuridine, 5-iododeoxyuridine, bromodeoxycytidine: Platinium coordination complexes; cisplatin, carboplatin: Anthracenedione; mitoxantrone, AQ4N Substituted urea, 10 hydroxyurea; Methylhydrazine derivatives, N-methylhydrazine (MIH), procarbazine; Adrenocortical suppressant, mitotane (o.p'-DDD), aminoglutethimide: Cytokines; interferon (a, 13, y), interleukin; Hormones and antagonists; adrenocorticosteroids/antagonists, prednisone and equivalents, dexamethasone, aminoglutethimide; Progestins, hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate; Estrogens, 15 diethylstilbestrol, ethynyl estradiol/equivalents; Antiestrogen, tamoxifen; Androgens, testosterone propionate, fluoxymesterone/equivalents; Antiandrogens, flutamide, gonadotropin-releasing hormone analogs, leuprolide; Nonsteroidal antiandrogens, flutamide; EGFR inhibitors, VEGF inhibitors; Proteasome inhibitors. Active compounds may also be used as cell culture additives to inhibit mTOR, for 20 example, in order to sensitize cells to known chemotherapeutic agents or ionising radiation treatments in vitro. Active compounds may also be used as part of an in vitro assay, for example, in order to determine whether a candidate host is likely to benefit from treatment with the compound in question. 25 Cancer The present invention provides active compounds which are anticancer agents or adjuncts for treating cancer. One of ordinary skill in the art is readily able to determine whether or not a candidate compound treats a cancerous condition for any particular cell type, either alone or in combination. 30 Examples of cancers include, but are not limited to, lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, WO 2007/060404 PCT/GB2006/004327 -49 pancreas cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma and leukemias. Any type of cell may be treated, including but not limited to, lung, gastrointestinal (including, e.g., bowel, colon), breast (mammary), ovarian, prostate, liver (hepatic), kidney 5 (renal), bladder, pancreas, brain, and skin. The anti cancer treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents: 10 (i) other antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5 fluorouracil and tegafur, raltitrexed, methotrexate, cytosine 15 arabinoside, and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamnycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere and polokinase inhibitors); and topoisomerase inhibitors (for example epipodophyllotoxins like 20 etoposide and teniposide, amsacrine, topotecan and camptothecin); (ii) cytostatic agents such as antioestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example 25 megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5*-reductase such as finasteride; (iii) anti-invasion agents (for example c-Src kinase family inhibitors like 4-(6 chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1 -yl)ethoxy]-5-tetrahydropyran 4-yloxyquinazoline (AZDO530; International Patent Application WO 01/94341) and N-(2 30 chloro-6-methylphenyl)-2- {6-[ 4 -(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4 ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825; J. Med. Chem., 2004, 47, 6658 6661), and metalloproteinase inhibitors like marimastat, inhibitors of urokinase plasminogen activator receptor function or antibodies to Heparanase); WO 2007/060404 PCT/GB2006/004327 - 50 (iv) inhibitors of growth factor function: for example such inhibitors include growth factor antibodies and growth factor receptor antibodies (for example the anti erbB2 antibody trastuzumab [HerceptinTM], the anti-EGFR antibody panitumumab, the anti erbB1 antibody cetuximab [Erbitux, C225] and any growth factor or growth factor receptor 5 antibodies disclosed by Stern et al. Critical reviews in oncology/haematology, 2005, Vol. 54, pp 1 1 -29); such inhibitors also include tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as N-(3-chloro- 4 -fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine 10 (erlotinib, OSI 774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3 morpholinopropoxy)-quinazolin-4-amine (CI 1033), erbB2 tyrosine kinase inhibitors such as lapatinib, inhibitors of the hepatocyte growth factor family, inhibitors of the platelet-derived growth factor family such as imatinib, inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for example sorafenib 15 (BAY 43-9006)), inhibitors of cell signalling through MEK and/or AKT kinases, inhibitors of the hepatocyte growth factor family, c-kit inhibitors, abl kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; aurora kinase inhibitors (for example AZD 1152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528 AND AX39459) and cyclin dependent kinase inhibitors such as CDK2 and/or CDK4 inhibitors; 20 (v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, [for example the anti vascular endothelial cell growth factor antibody bevacizumab (AvastinTM) and VEGF receptor tyrosine kinase inhibitors such as 4 (4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline (ZD6474; Example 2 within WO 01/32651), 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy 25 7-(3-pyrrolidin-1-ylpropoxy)quinazoline (AZD2171; Example 240 within WO 00/47212), vatalanib (PTK787; WO 98/35985) and SUl 1248 (sunitinib; WO 01/60814), compounds such as those disclosed in International Patent Applications WO97/22596, WO 97/30035, WO 97/32856 and WO 98/13354 and compounds that work by other mechanisms (for example linomide, inhibitors of integrin avb3 function and angiostatin)]; 30 (vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213; WO 2007/060404 PCT/GB2006/004327 -51 (vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense; (viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene directed enzyme 5 pro drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi drug resistance gene therapy; and (ix) immunotherapy approaches, including for example ex vivo and in vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with 10 cytokines such as interleukin 2, interleukin 4 or granulocyte macrophage colony stimulating factor, approaches to decrease T cell anergy, approaches using transfected immune cells such as cytokine transfected dendritic cells, approaches using cytokine transfected tumour cell lines and approaches using anti idiotypic antibodies. Administration 15 The active compound or pharmaceutical composition comprising the active compound may be administered to a subject by any convenient route of administration, whether systemically/ peripherally or at the site of desired action, including but not limited to, oral (e.g. by ingestion); topical (including e.g. transdermal, intranasal, ocular, buccal, and sublingual); pulmonary (e.g. by inhalation or insufflation therapy using, e.g. an aerosol, e.g. 20 through mouth or nose); rectal; vaginal; parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot, for example, subcutaneously or intramuscularly. 25 The subject may be a eukaryote, an animal, a vertebrate animal, a mammal, a rodent (e.g. a guinea pig, a hamster, a rat, a mouse), murine (e.g. a mouse), canine (e.g. a dog), feline (e.g. a cat), equine (e.g. a horse), a primate, simian (e.g. a monkey or ape), a monkey (e.g. marmoset, baboon), an ape (e.g. gorilla, chimpanzee, orangutang, gibbon), or a human. Formulations 30 While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (e.g., formulation) comprising at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilisers, preservatives, lubricants, or other WO 2007/060404 PCT/GB2006/004327 - 52 materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents. Thus, the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least 5 one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, stabilisers, or other materials, as described herein. The term "pharmaceutically acceptable" as used herein pertains to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical 10 judgement, suitable for use in contact with the tissues of a subject (e.g. human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation. Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical 15 texts. See, for example, refs. 27 to 29. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and 20 intimately bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product. Formulations may be in the form of liquids, solutions, suspensions, emulsions, elixirs, syrups, tablets, lozenges, granules, powders, capsules, cachets, pills, ampoules, suppositories, pessaries, ointments, gels, pastes, creams, sprays, mists, foams, lotions, oils, boluses, 25 electuaries, or aerosols. Formulations suitable for oral administration (e.g., by ingestion) may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion; as 30 a bolus; as an electuary; or as a paste. A tablet may be made by conventional means, e.g. compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or WO 2007/060404 PCT/GB2006/004327 - 53 granules, optionally mixed with one or more binders (e.g. povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g. lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc, silica); disintegrants (e.g. sodium starch glycolate, cross-linked povidone, cross-linked sodium 5 carboxymethyl cellulose); surface-active or dispersing or wetting agents (e.g., sodium lauryl sulfate); and preservatives (e.g., methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, sorbic acid). Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the 10 active compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach. Formulations suitable for topical administration (e.g. transdermal, intranasal, ocular, buccal, and sublingual) may be formulated as an ointment, cream, suspension, lotion, powder, 15 solution, past, gel, spray, aerosol, or oil. Alternatively, a formulation may comprise a patch or a dressing such as a bandage or adhesive plaster impregnated with active compounds and optionally one or more excipients or diluents. Formulations suitable for topical administration in the mouth include losenges comprising the active compound in a flavored basis, usually sucrose and acacia or tragacanth; 20 pastilles comprising the active compound in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active compound in a suitable liquid carrier. Formulations suitable for topical administration to the eye also include eye drops wherein the active compound is dissolved or suspended in a suitable carrier, especially an 25 aqueous solvent for the active compound. Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable 30 formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebuliser, include aqueous or oily solutions of the active compound.

WO 2007/060404 PCT/GB2006/004327 - 54 Formulations suitable for administration by inhalation include those presented as an aerosol spray from a pressurised pack, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases. 5 Formulations suitable for topical administration via the skin include ointments, creams, and emulsions. When formulated in an ointment, the active compound may optionally be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active compounds may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example, at least about 10 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active compound through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related 15 analogues. When formulated as a topical emulsion, the oily phase may optionally comprise merely an emulsifier (otherwise known as an emulgent), or it may comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also 20 preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax, and the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Suitable emulgents and emulsion stabilisers include Tween 60, Span 80, cetostearyl 25 alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulphate. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations may be very low. Thus the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or 30 other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred WO 2007/060404 PCT/GB2006/004327 - 55 esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used. Formulations suitable for rectal administration may be presented as a suppository with 5 a suitable base comprising, for example, cocoa butter or a salicylate. Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active compound, such carriers as are known in the art to be appropriate. Formulations suitable for parenteral administration (e.g., by injection, including 10 cutaneous, subcutaneous, intramuscular, intravenous and intradermal), include aqueous and non-aqueous isotonic, pyrogen-free, sterile injection solutions which may contain anti oxidants, buffers, preservatives, stabilisers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and 15 liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. Examples of suitable isotonic vehicles for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection. Typically, the concentration of the active compound in the solution is from about 1 ng/ml to about 10 pgg/ml, for example from about 10 ng/ml to about 1 ptg/ml. The 20 formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets. Formulations may be in the form of liposomes or other 25 microparticulate systems which are designed to target the active compound to blood components or one or more organs. Dosage It will be appreciated that appropriate dosages of the active compounds, and compositions comprising the active compounds, can vary from patient to patient. 30 Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects of the treatments of the present invention. The selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of WO 2007/060404 PCT/GB2006/004327 - 56 administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, and the age, sex, weight, condition, general health, and prior medical history of the patient. The amount of compound and route of administration will ultimately be at the discretion of the physician, although generally the 5 dosage will be to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects. Administration in vivo can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those 10 of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. In general, a suitable dose of the active compound is in the range of about 100 ptg to 15 about 250 mg per kilogram body weight of the subject per day. Where the active compound is a salt, an ester, prodrug, or the like, the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately. Examples General Experimental Methods 20 Thin Layer chromatography was carried out using Merck Kieselgel 60 F 254 glass backed plates. The plates were visualized by the use of a UV lamp (254 nm). Silica gel 60 (particle sizes 40-63 pm) supplied by E.M.Merck was employed for flash chromatography. 'H NMR spectra were recorded at 300 MHz on a Bruker DPX-300 instrument. Chemical shifts were referenced relative to tetramethylsilane. 25 Purification and identification of library samples The samples were purified on Gilson LC units. Mobile phase A - 0.1% aqueous TFA, mobile phase B - Acetonitrile; flow rate 6 ml/min; Gradient - typically starting at 90% A/10% B for 1 minute, rising to 97% after 15 minutes, holding for 2 minutes, then back to the starting conditions. Column: Jones Chromatography Genesis 4gm, C18 column, 10 mm x 30 250 mm. Peak acquisition based on UV detection at 254 nm. Mass spectra were recorded on a Finnegan LCQ instrument in positive ion mode. Mobile phase A - 0.1% aqueous formic acid. Mobile phase B - Acetonitrile; Flowrate 2 ml/min; Gradient - starting at 95% A/5% B for 1 minute, rising to 98% B after 5 minutes and WO 2007/060404 PCT/GB2006/004327 - 57 holding for 3 minutes before returning to the starting conditions. Column: Varies, but always C18 50 mm x 4.6 mm (currently Genesis C18 4 Ipm. Jones Chromatography). PDA detection Waters 996, scan range 210-400 nm. Microwave synthesis 5 Reactions were carried out using a Personal ChemistryTM Emrys Optimiser microwave synthesis unit with robotic arm. Power range between. 0-300 W at 2.45 GHz. Pressure range between 0-20 bar; temperature increase between 2-5 0 C/sec; temp range 60-250 0 C. Synthesis of 2,4,7-substituted pyridopyrimidine derivatives 0 0 0 O O O OH OH NH 2 Cl N CI CI N NH 2 Cl N NH 2 Inter. 1 Inter. 2 Inter. 3 0 CI NH ~ ~ Cl N N O H CI N N Cl Inter. 4 Inter. 5

R

4 N 2 R C N N R Inter. 7 R4 NN Cl N N CI I 7 2 Inter. 6 R4 R N N R Example Compounds R N N CIl 10 Inter. 8 WO 2007/060404 PCT/GB2006/004327 - 58 Intermediates: a) 2-Amino-6-chloronicotinic acid (Inter. 2) To 2,6-dichloronicotinic acid (Inter. 1)(1 equiv) was added liquid ammonia (sufficient to make a 0.6M solution of substrate in ammonia). The suspension was sealed in a pressure 5 vessel which was then heated slowly to 130 0 C. It was noted that at this temperature a pressure of 18 bar was observed. This temperature and pressure was maintained for a further 16 hours whereupon the mixture was cooled to room temperature. The pressure vessel was opened and the reaction poured into ice cold water (1 reaction volume). The resulting solution was acidified to pH 1-2 using concentrated HCI which caused a precipitate to form. The acidic 10 mixture was allowed to warm to room temperature and was stirred like this for a further 30 minutes. The suspension was then extracted with diethyl ether (3 x 400 ml). The combined organic extracts were then filtered and the filtrate concentrated in vacuo to give a white solid which was dried further over P 2 0 5 to give the title compound (90% yield and 96% pure) in suitably pure form to be used without any further purification. m/z (LC-MS, ESP): 173 15 [M+H] + PR/T = 3.63 mins b) 2-Amino-6-chloronicotinamide (Inter. 3) To a 0.3 M solution of 2-amino-6-chloronicotinic acid (Inter. 2)(1 equiv) in anhydrous THF, under an inert atmosphere, was added thionyl chloride (3.3 equiv) in a 20 dropwise fashion. The reaction mixture was stirred at room temperature for 2 hours. After this time the reaction was concentrated in vacuo to give a crude yellow solid residue. The crude solid was dissolved in THF (equal to initial reaction volume) and concentrated in vacuo again to give a yellow solid residue. The residue was dissolved once more in THF and concentrated as before to give a solid residue which was then dissolved in THF (to give a 25 solution of 0.3M) and ammonia gas bubbled through the solution for 1 hour. The resultant precipitate was removed by filtration and the filtrate concentrated in vacuo to give a yellow precipitate which was triturated with water at 50 0 C then dried to give the title compound (92% yield, 93% purity), suitably clean to be used without any further purification. m/z (LC MS, ESP): 172 [M+H] + R/T = 3.19 mins 30 c) 7-Chloro-1H-pyrido[2,3-d]pyrimnidine-2,4-dione (Inter. 4) To a stirred solution (0.06 M) of 2-amino-6-chloronicotinamide (Inter. 3)(1 equiv) in anhydrous toluene under an inert atmosphere was added oxalyl chloride (1.2 equiv) in a WO 2007/060404 PCT/GB2006/004327 - 59 dropwise manner. The resulting mixture was then heated to reflux (115 0 C) for 4 hours whereupon it was cooled and stirred for a further 16 hours. The crude reaction mixture was then concentrated to half its volume in vacuo and filtered to give the desired product in suitably pure form (95% yield, 96% purity) to be used without any further purification. m/z 5 (LC-MS, ESP): 196 [M-H]- R/T = 3.22 mins d) 2,4,7-Trichloro-pyrido[2,3-d]pyrimidine (Inter.5) To a stirred 0.5 M suspension of the dione (Inter. 4)(1 equiv.) in anhydrous toluene under an inert atmosphere was slowly added diisopropylethylamine (3 equiv.). The reaction 10 mixture was then heated to 70 0 C for 30 minutes and then cooled to room temperature prior to the addition of POCl 3 (3 equivalents). The reaction was then heated to 100 0 C for 2.5 hours before being cooled and concentrated in vacuo to give a crude slurry which was then suspended in EtOAc and filtered through a thin pad of CeliteTM. The filtrate was concentrated in vacuo to give a brown, oil which was dissolved in CH 2

C

2 and stirred over silica gel for 30 15 minutes. After this time the silica was removed by filtration, the filtrate concentrated and the crude residue purified by flash chromatography (SiO 2 ) to give the title compound in analytically pure form (48% yield, 96% purity). m/z (LC-MS, ESP): 234 [M+H] + R/T = 4.21 mins 20 e) 4-Amnino-2,7-dichloropyridopyrimidines (Inter. 6) To a cooled (0-5 0 C) stirred solution (0.1 M) of the trichloro substrate (Inter. 5)(1 equiv.) in CH 2

C

2 was added diisopropylethylamine (1 equiv.) in a dropwise fashion. The appropriate amine (1 equiv.) was then added to the reaction mixture portionwise over the period of 1 hour. The solution was maintained at room temperature with stirring for a further 25 1 hour before the mixture was washed with water (2 x 1 reaction volume). The aqueous extracts were combined and extracted with CH2C1 2 (2 x 1 reaction volume). The organic extracts were then combined, dried (sodium sulphate), filtered and concentrated in vacuo to give an oily residue which solidified upon prolonged drying. The solid was triturated with diethylether and then filtered and the cake washed with cold diethyl ether to leave the title 30 compound in suitable clean form to be used without any further purification. Inter. 6a: 2,7-Dichloro-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; R 4= morpholino; (92% yield, 90% purity) m/z (LC-MS, ESP): 285 [M+H]

+

R/T = 3.90 mins WO 2007/060404 PCT/GB2006/004327 - 60 Inter. 6b: 2 ,7-Dichloro-4-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-pyrido[2,3 d]pyrimidine; R 4 =(2R,6S)-2,6-Dimethyl-morpholino; (99% yield, 90% purity) m/z (LC-MS, ESP): 313 [M+H] R/T= 4.39 mins 5 J) 2,4-Diamino-7-chloropyridopyrimidines (Inter. 7) To a solution (0.2 M) of the appropriate dichloro-substrate (Inter. 6a or 6b)(1 equiv) in anhydrous dimethyl acetamide under an inert atmosphere was added diisopropylethylamine (1 equiv) followed by the appropriate amine (1 equiv.). The resulting mixture was heated for 48 hours at 70oC before being cooled to ambient temperature. The reaction was diluted with 10 CH 2 C1 2 (1 reaction volume) and then washed with water (3x1 reaction volumes). The organic extract was concentrated in vacuo to give a syrup which was dissolved in EtOAC (1 reaction volume) and washed with saturated brine solution before being dried (sodium sulphate) and concentrated in vacuo to give an oil. The crude residue was purified by flash chromatography (SiO 2 , eluted with EtOAc:Hex (7:3) going to (1:1)) to give the title compound as a yellow 15 solid that was suitably clean to be used without any further purification. Inter. 7a: 7 -Chloro- 2 -((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl pyrido[2,3-d]pyrimidine;

R

4 = morpholine, R 2 = cis-dimethylmorpholine; (45% yield, 85% purity) m/z (LC-MS, ESP): 348 [M+H] + R/T = 4.16 mins 20 Inter. 7b: 7-Chloro-4-(2-methyl-piperidin-1 -yl)-2-morpholin-4-yl- -pyrido[2,3 d]pyrimidine; R 4 = morpholine, R 2 =2-methylpiperidine; (57% yield, 95% purity) m/z (LC MS, ESP): 348.1 [M+H] + R/T = 3.42 mins Inter. 7c: 7 -Chloro- 4 -((2S,6R)-2,6-dimethyl-morpholin-4-yl)-2-((S)-3-methyl morpholin-4-yl)pyrido[2,3-d]pyrimidine (intermediate for compound 11k:) R 4 = cis 25 dimethylmorpholine, R 2 = (S)-3-Methyl-morpholine; (48% yield, 90% purity) m/z (LC-MS, ESP): 378 [M+H] + R/T = 3.74 mins Inter. 7d: 7-Chloro-2-((S)-3-methyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3.

d]pyrimidine (Intermediate for compound 1 la): R 4 = morpholine, R 2 = (S)-3-Methyl morpholine; (70% yield, 97% purity) m/z (LC-MS, ESP): 350 [M+H] + R/T = 3.44 mins 30 Inter. 7e: 7-Chloro-2-(2-ethyl-piperidin-1-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine (intermediate for compound 1 lay): R 4 = morpholine, R 2 = 2-Ethyl-piperidine; (56% yield, 95% purity) m/z (LC-MS, ESP): 362 [M+H]

+

R/T = 3.78 mins WO 2007/060404 PCT/GB2006/004327 -61 g) 4-amino- 7 -atyl-2-chloropyridopyrimidines (Inter. 8) To a solution (0.09 M) of the appropriate boronic acid or ester (1 equiv) in water (1 volume) was added the appropriate 2,7-dichloro-4-amino pyridopyrimidine (1 equiv) (Inter. 6a or 6b) potassium carbonate (2.5 equiv) and acetonitrile (1 volume). The mixture was 5 degassed by bubbling nitrogen through the solution while sonicating for 15 minutes before the addition of by tetrakis(triphenylphosphine) palladium (0.03 equiv). The mixture was degassed for a further 5 minutes before heating under an inter atmosphere at 95 OC for 2 hours. Upon completion, the reaction was cooled to room temperature and filtered under vacuum. The filtrate was concentrated in vacuo to give a solid residue which was dissolved in CH 2

C

2 (1 10 volume) and washed with water (1 volume). The organic extract was then dried (MgSO 4 ), filtered and concentrated in vacuo to give an amorphous solid which was triturated with Et 2 O to leave the desired product as a fine powder. Inter. 8a (R 4 =Morpholine, R 7 = 4-chlorophenyl) 2 -Chloro-7-(4-chloro-phenyl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; 1H NMR (300 15 MHz, Solvent CDCI 6ppm 8.29-7.96 (mn, 2H), 7.75 (d, J= 8.70 Hz, 1H), 7.54-7.21 (mn, 2H), 5.29 (s, 1H), 3.91 (in, 8H). Example 1 20 R 7 =aryl (Examples la-bx) The appropriate chloro-substrate (Inter. 7a-e)(1 equiv.) was dissolved in a toluene/ethanol (1:1) solution (0.02 M). Sodium carbonate (2 equiv.) and the appropriate boronic acid (1 equiv.) were then added followed by tetrakis(triphenylphosphine) palladium (0.1 equiv). The reaction vessel was sealed and the mixture exposed to microwave radiation 25 (140 0 C, medium absorption setting) for 30 minutes. Upon completion the samples were filtered through a silica cartridge, washed with EtOAc and then concentrated in vacuo. The crude residue was then purified by preparative HPLC to give the compounds listed below. 30 WO 2007/060404 PCT/GB2006/004327 - 62 R R R Retention [m/z] Purity Time (%) (mins) la OH 0 * 7.66 466.6 89 MeO I * lb N * O * N ' 9.56 440.4 85 0O Cl N I 1c * 0 8.57 406.5 88 N I * id )* o N 4.56 420.5 89 N * le * O *N.. 4.41 436.5 98 MeO N * if 4.13 452.3 99 OH 0 N "N- of-.,..

WO 2007/060404 PCT/GB2006/004327 - 63 R R 4

R

z Retention [rm/z] Purity Time (%) (mins) ig 4.82 424 99 o N- Cl lh 4.66 390.1 96 0 N-+ li 8.12 412.3 93 s 0 N+. + lj 4.38 450.1 96 OH 0o N- WO 2007/060404 PCT/GB2006/004327 - 64 R R 4 R Retention [m/z] Purity Time (%) (mins) 1k 7.75 482.5 0 N- . .. ,,# H 0 + 89 11 7.88 422.4 99 + Im 9.08 478.4 99 HOO , + In 8.52 431.4 95 / \_ 0 - N \../ WO 2007/060404 PCT/GB2006/004327 - 65 R R 4

R

2 Retention [m/z] Purity Time (%) (mins) lo 3.89 456.4 93 OH O NW E pO O0 OH lp 4.36 480.5 100 CH T ° ' lq 4.09 436.4 100 OH 0 46 + Ir 4.03 396.2 100 0 N

+

WO 2007/060404 PCT/GB2006/004327 - 66 R 7 R R 2 Retention [m/z] Purity Time (%) (mins) is 10.19 404.2 97 0 N 0 it 4.66 426.3 98 + lu 4.67 420.1 95 0.-* lv 4.53 426.3 99 0 + lw 9.11 454.4 100 F N-

F

WO 2007/060404 PCT/GB2006/004327 - 67 R R 4

R

2 Retention [m/z] Purity Time (%) (mins) lx 8.93 445.3 97 NH O ',, , + ly 4.72 426.4 99 o- N-4 + lz 8.89 451.5 80 0 + laa 7.66 396.4 99 O O N

+

WO 2007/060404 PCT/GB2006/004327 - 68 R R 4

R

2 Retention [m/z] Purity Time (%) (mins) lab 7.65 463.4 85 - 0 U + H N lac 3.62 407.4 99 N o + lad 7.06 410.4 99 N- 0 + lae 4.24 466.5 100 OH

SON+

WO 2007/060404 PCT/GB2006/004327 - 69

R

7

R

4

R

2 Retention [m/z] Purity Time (%) (mins) laf 4.33 484.4 96 OH O N lag 4.44 454.3 98 o + lah 8.43 466.4 97 0 0 N+i + lai 6.98 449.4 100 o N

NH

2 laj 9.06 420.4 90

+

WO 2007/060404 PCT/GB2006/004327 - 70 R R 4

R

2 Retention [m/z] Purity Time (%) (mins) lak 8.95 450.4 96 o O+ lal 9.45 446.2 88 CI + lam 8.92 464.4 99 / lo lan 9.85 456.4 97 0,_____

+

WO 2007/060404 PCT/GB2006/004327 -71 R 7

R

2 Retention [m/z] Purity Time (%) (mins) lao 10.42 490.4 97 o F + lap 4.41 440.3 99 + laq 8.4 448.5 97 laq 84 1 o N+ -. + lar 7.66 456.4 99 OH 0 N4

O+

WO 2007/060404 PCT/GB2006/004327 - 72 R 7 R R 2 Retention [m/z] Purity Time (%) (mins) las 8.46 491.5 99 o + lat 8.97 464.4 99 0\,, t,., + lau 8.35 431.5 93 lay 8.59 450.4 99 0 N-" 0 \ / o .. + WO 2007/060404 PCT/GB2006/004327 - 73 R R R2 Retention [m/z] Purity Time (%) (mins) 1aw 10.1 462.4 98 / ___ 0 + 6.03 407.4 100 lax + 7.63 457.5 99 lay 0 -+ \9 N 1az 6.4 408.4 99 laz -+ N+

-<N

WO 2007/060404 PCT/GB2006/004327 - 74 R R R Retention [m/z] Purity Time (%) (mins) lba 9.08 478.4 99 O // 0 + lbb 3.95 452.3 95 OH 0 H + lbc 9.01 464.4 99 OH O N+ lbd O 4.69 464.3 98 0 N- 4.31426,10 ibe 4.31 426.3 100 o N- " .

WO 2007/060404 PCT/GB2006/004327 - 75 R R 7

R

2 Retention [m/z] Purity Time (%) (mins) lbf 4.9 512.4 100 0 -... . lbg 7.82 449.5 90 HO + lbh 8.18 463.5 89 lbi 3.89 426.4 100 1bj LA H5.45 353.2 100 10 N+ ; OH lbj 115.45 353.2 10095 0 N "OH lbk , 5.43 518.4 96 + lbl To-o .,,,,. ,, 11.28 502.3 95

+

WO 2007/060404 PCT/GB2006/004327 - 76 R 7

R

4

R

2 Retention [m/z] Purity Time (%) (mins) ibm o 4.13 480.4 97 + lbn 4.79 464.4 97 + lbo 5.2 492.4 93 o N4 + lbp OH 4.5 508.4 90 0,O , + lbq 4.81 476.4 100 + lbr O/- 9.44 450.3 98 0 4 2 + lbs + 4.65 424.3 99 '-0 N-,-j WO 2007/060404 PCT/GB2006/004327 - 77

R

7

R

4

R

2 Retention [m/z] Purity Time (%) (mins) lbt ,- 9.26 506.3 98 0 N + 1bu 4.78 438.4 99 Cl o N-j lbv - 11.43 526.3 99 - 0- ,,,, .. , + lbw F 11.54 548.3 98 + lbx 5.37 506.4 95 0 N+ + Example lbj:- 1H NMR (300 MHz, Solvent CDC1 3 ) 8 ppm 8.72 (s, 1H), 8.46 (d, J = 8.70), 8.37 d, 2.34 Hz, 1H), 8.17 (dd, J= 8.60, 2.34 Hz, 1H), 8.02 (d, J= 8.77 Hz, 1H), 7.14 (d, J 8.68 Hz, 1H), 4.59 (s, 1H), 3.95-3.71 (m, 8H), 2.50 (m, 3H). 5 Example 2

R

7 =Substituted Amino (Examples 2a-2bg) To a solution of the appropriate chloro-substrate (Inter. 7a-e)(1 equiv.) in 1,4-dioxane (0.04M) was added the appropriate amine (1.2 equiv.), cesium carbonate (2 equiv.), WO 2007/060404 PCT/GB2006/004327 - 78 XantphosTM and tris(dibenzylideneacetone)dipalladium(0). The reaction vessel was sealed and exposed to heating under the influence of microwave radiation (normal absorption setting, 150 0 C, 20 minutes). The crude reaction mixture was then purified by preparative HPLC to give the compounds listed below. 5

R

4 R R Purity m/z RT % [MH] (mins) 2a o *N / 95 421 4.65 N N N O N I H * 2b o0O 96 513 4.12 IO H 2c o N a HO 2 C 95 451 3.6 <N) E N0 N N - H * OH 2d CO *N 98 373.1 7.18 N N 2e 0' 83 389.2 3.73 N : . \N/* N H 2f 0 /" 100 472.2 3.49 0 2g CO N 96 479.5 8.81 N) o MeO2C N2 * N *

H

WO 2007/060404 PCT/GB2006/004327 - 79 R R R 7 Purity m/z RT % [MHI (mins) 2h NC 85 446.5 8.34 N> N H 2i *0 91 405.5 9.41 N "N H 2j *N99 435.5 4.61 CN) N"' I H 2k * ' CI 86 455.5 9.68 * H 21 O0 2 96 514.5 9.38 0 N N I H * CI 2m 0) 100 525.6 10.46 oa N N 0 H * 0 2n . N 96 463.6 10.62 N N H 2o o % 92 472.5 9.44 o N N N

H

WO 2007/060404 PCT/GB2006/004327 - 80 S R R 7 Purity m/z RT % [MHI + (mins) 2p O MeO 98 553.6 11.83 N \*/ N H 2q Cos 97 486.6 10.22 ONN * H *2r . N 100 412.4 3.5 2r ) -NN N N I H 2s o.. 92 538.2 10.59 N O N N N " H ICl *OF N 2t < O> ,," 86 436.2 3.44 N L-z N H 2u 60) *-> F 81 459.4 4.26 2v O ".K* 88 399.6 7.96 N 2w o~F N N90 442.6 5.13 H 2v (0) N N ~ 88 399.6 7.96 > 0 H Io o N 2w ~90 442.6 5.13 2x O " ', ... 94 426.4 8.52 N : * . H WO 2007/060404 PCT/GB2006/004327 -81

S

R

2 R Purity m/z RT % [MH]+ (mins) 2y *'O N11N 95 515.6 8.71 N N N H 2z * .' F. 92 445.4 9.49 H 2aa o * c, 98 471.5 9.04 N I0N' O-H . OH 2ab (O Et 2 N 69 492.6 6.25 N aN I - H 2ac 0 . .F 73 502.5 9.48 No F SN/* N H

NO

2 2ad " S N S 97 524.2 9.68 N "

.

N* H 2ae "0 N 96 525.4 4.79 H 2af * "98 427.5 4.55 N N I = H WO 2007/060404 PCT/GB2006/004327 - 82 R 4 R R 2 Purity m/z RT % [MH + (mins) 2ag o *'O 100 413.4 4.36 N H 2ah *N o 95 385.3 3.88 N H 2ai * 'N 89 399.5 8.13 N H I 2aj (O *" N 94 399.5 8.18 N I 2ak * 91 378.4 7.81 y : H 2al 0o ' ],O... 99 441.6 9.95 NON I H 2am O * N/* 92 385.5 7.46 o H N I " 2an (o *' MeO.C \99 469.4 4.31 MeO 2 C N N H 2ao N- * N 98 427.5 3.91 N 0 N I -H WO 2007/060404 PCT/GB2006/004327 - 83 R R 2

R

' Purity m/z RT % [MH] (mins) 2ap 0 .

CN 83 512.2 4.97 ap N 0 N IH 2aq o * S N 94 427.1 94 N H 2ar o H CN 99 436.1 3.9 N N N H 2as O HN* 98 482.1 4.36 No •N

CO

2 Me 2at (0 *-N MeO 98 510.5 8.96 N N N H * OMe 2au O ..... N H 98 463.6 4.03 N O N N NN * H 2av 0 o 99 473.6 4.12 N o H N 2aw N 99 500.6 4.17 2ax O *N " N 82 489.5 4.84 N N N

H

WO 2007/060404 PCT/GB2006/004327 - 84 R R R 7 Purity m/z RT % [MH] (mins) 2ay (O *'O OH 98 488.5 4.56 N N * \ N N H 2az (o) *N .

100 422.5 3.73 N N - H 2ba (o0 * 100 422.5 3.6 0 N. N N H 2bb <0> N" 99 423.5 3.94 N N N* -H 2bc ) * " N 97 423.5 4.11 N .:N/ NN~ . H 2bd o *

I

'

N 100 436.5 4.00 N H 2be Co) * 99 436.5 4.49 0 N N N I = H 2bf O . HN/* 95 544.6 5.23 N, N N N

NH

WO 2007/060404 PCT/GB2006/004327 - 85 R 4 R R 2 Purity m/z RT % [MH] + (mins) 2bg * "' 99 436.5 3.94 N N I H 2bf (0 +H 5.35 330.3 96 + Example 2bf:- 1H NMR (300 MHz, Solvent CDCl 3 ) 6 ppm 8.50 (s, 1H), 8.05 (d, J= 9.32 Hz, 1H), 7.10 (d, J= 9.37 Hz, 1H), 4.46 (d, J= 12.95 Hz, 1H), 3.82-3.50 (min, 11H), 3.31 (s, 1H), 2.70-2.43 (min, 4H), 1.17 (d, J= 6.30 Hz, 1H) 5 Example 3

R

7 = NH 2 (Examples 3a-b) To a solution of the appropriate chloro-substrate (Inter. 7a-e)(1 equiv) in isopropanol (0.6 M) was added concentrated aqueous ammonia solution (5 volumes). The reaction vessel 10 was sealed and heated under the influence of microwave radiation (high absorption setting, 150 0 C, 30 minutess). The reaction mixture was then cooled, diluted with water (3 volumes) and extracted with EtOAc (2x3 volumes). The combines organic extracts were dried (sodium sulphate), filtered and concentrated in vacuo to give a crude residue that was further purified by flash chromatography (SiO 2 ) (Eluent-EtOAc/MeOH (95:5) going to (9:1)) to give the 15 compounds below in analytically pure form. 20 WO 2007/060404 PCT/GB2006/004327 - 86 R 4

R

2

R

7 Purity m/z RT % [MH] (mins) 3a o *N .. ' 95 345.2 3.86 0 1-1* N H2N 3b N 91 329.4 7.33 N ,"H 2 N * Example 4

R

7 =Urea (Examples 4a-i) To a solution (0.02M) of the appropriate amino-substrate (e.g. Example 3a or 3b)(1 5 equiv.) in anhydrous THF was added the appropriate isocyanate (2 equiv.). The reaction vessel was sealed and heated to 60 0 C for 1 hour. The crude reaction mixture was then purified by preparative HPLC to give the compounds below.

R

4 R R Purity m/z RT % [MH]+ (mins) 4a 0 0 ... O 99 416.5 3.8 N H H * 10 Example 5

R

7 =Amido (Examples 5a-g) To a solution (0.02M) of the appropriate amine-substrate (Example 3a or 3b)(1 equiv) in anhydrous CH 2

CI

2 was added triethylamine (2 equivalents) and the appropriate acid chloride (2 equivalents). The mixture was stirred at room temperature for 1 hour whereupon 15 the solvent was allowed to evaporate at atmospheric pressure and the crude residue purified by preparative HPLC to give the compounds below.

WO 2007/060404 PCT/GB2006/004327 - 87

R

4 R R 7 Purity % m/z RT [MH] (mins) 5a o * o 95 402.2 4.49 <N) * 0 o H 5b (o 0 ) *N *.. 96 441.2 4.16 0N N H. 5c Co..O 100 413.2 3.89 N -N I H 5d 0 - 0 98 495.2 4.34 N H I H 5e (o) * 83 501.2 4.28 N H * N 5f oI 0 95 387.2 6.04 N- H 5g O * .. 99 454.5 3.85 LiN N~ IN H NH 2 Example 6

R

7 =Sulfonamido To a solution (0.02M) of the appropriate amine-substrate (Example 3a or 3b)(1 5 equiv.) in anhydrous CH 2 C1 2 was added triethylamine (2 equiv.) and the appropriate sulfonyl chloride (2 equiv.). The mixture was stirred at room temperature for 1 hour whereupon the solvent was allowed to evaporate at atmospheric pressure and the crude mixture purified by preparative HPLC to give the desired product.

WO 2007/060404 PCT/GB2006/004327 - 88 R 4 R R Purity m/z RT % [MH] (mins) 6N 0 85 423.5 3.87 ONSN N H I Example 7

R

7= alkoxy To a solution of the appropriate chloro-substrate (Inter. 7a-e) (1 equiv.) in the 5 appropriate alcohol solvent (0.16 M) was added potassium carbonate (5 equiv.). The reaction vessel was sealed and heated under the influence of microwave radiation (160 0 C, high absorption setting, 30 minutes). The reaction mixture was then concentrated to dryness and purified by preparative HPLC to give the desired product. R R 2

R

7 Purity m/z RT % [MH] (mins) 7 O O ' 100 402.2 4.49 N I 10 Example 8

R

7 = 4-alkoxy-3-aminomethyl-phenyl (Examples 8a - 8bh) N N MsCI, Et N, O " N DCM CI N N N N-"N "' N NN 'O ' 00 Amines R N oN N WO 2007/060404 PCT/GB2006/004327 - 89 To a 0.1 M solution of Example la (1 equiv.) in CH 2 C1 2 was added Et 3 N (1 equiv.) followed by methanesulfonyl chloride (1.1 equiv.) which was added dropwise. The reaction was stirred under an inert atmosphere for 90 minutes whereupon it was quenched with water 5 (2x1 volume), the organis extract separated and dried (MgSO 4 ) filtered and concentrated in vacu. The crude yellow gum was then diluted in diethyl ether and stirred vigorously. The resultant yellow precipitate was then collected by filtration to give the title compound (98%) in suitable clean form to be used without further purification. 10 7-(3-Chloromethyl-4-methoxy-phenyl)-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4 morpholin-4-yl-pyrido[2,3-d]pyrimidine; (98.9% yield, 94% purity) m/z (LC-MS, ESP): Did not ionise [M+H] R/T = 3.98 mins To a 0.03 M solution of 7-(3-Chloromethyl-4-methoxy-phenyl)-2-((2S,6R)-2,6 15 dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine (1 equiv.) in dimethylformamide was added potassium carbonate (2.6 equiv.) followed by the triethylamine (1 equiv.) and finally the appropriate amine (1.1 equiv.). The reaction mixture was then heated to 40 oC for 16 hours whereupon it was purified by preparative HPLC to give the desired product. Purity Retention [m/z] (%) time (mins) 8a 99 3.86 519.5 8b77 . N 0,b7. 8b 77 6.32 WO 2007/060404 PCT/GB2006/004327 - 90 Purity Retention [m/z] (%) time (mins) 8c 98 5.29 559.5 N N H N o N Z0 8d 98 5.96 509.4 HO AN 0 8e 87 7.56 599.5 NN 0 8f 100 6 479.5 (0) N 'NH N N ~ 0 8g 99 3.88 519.5 (0 N A' N N N -N N I-) 0 7 LN0 WO 2007/060404 PCT/GB2006/004327 -91 Purity Retention [m/z] (%) time (mins) 8h 99 3.57 578.5

'N

0 ~0 8i 99 6.21 549.6 8j 95 6.97 561.5 A 8k 99 6.8 533.5 89 9N No N 81 99 3.95 521.5 0NN "N 0'N ~ N WO 2007/060404 PCT/GB2006/004327 - 92 Purity Retention [m/z] (%) time (mins) 8m 99 4.04 535.4 8n 99 4.18 575.5 N -HN 8o 99 7.14 547.5 8p 75 7.75 561.5 8" N9N9H N 8q 99 4.12 549.4

"N"H

WO 2007/060404 PCT/GB2006/004327 - 93 Purity Retention [m/z] (%) time (mins) 8r 93 6.36 507.6 8s 100 6.71 551.5 o 8t 99 4.11 549.5 N N N. N' '-. N NN N) 0... .... 0 8u 98 6.73 521.5 8v 99 6.25 523.4

N

f 0 @ WO 2007/060404 PCT/GB2006/004327 - 94 Purity Retention [m/z] (%) time (mins) 8w 99 4.1 561.5 -0 8x 99 4.14 571.4 0 N' " I ' N N N -. N .7 0 0 8y 99 4.12 658.4 0 0 CH 8z 99 4.07 615.5 (0 N ' N 8aa 99 3.73 577.4 N 0OY H~ WO 2007/060404 PCT/GB2006/004327 - 95 Purity Retention [m/z] (%) time (mins) 8ab 99 3.81 591.4 8ac 99 3.92 619.4 8ad 99 3.55 569.3 HOS,'H N HOH N N 0 00 8ae 99 3.42 662.3 a ,H N N/ o 8af 99 4.01 519.4 0 0

H

WO 2007/060404 PCT/GB2006/004327 - 96 Purity Retention [m/z] (%) time (mins) 8ag 99 3.96 575.3 0N H0 8ah 99 4.12 573.5 8ai 99 3.61 576.5 A N N ~~0 8aj 99 3.91 549.4 0 N N H N 8ak 99 4.01 553.4 0II WO 2007/060404 PCT/GB2006/004327 - 97 Purity Retention [m/z] (%) time (mins) 8al 83 4.18 531.4 N HNN N o N N..... 8am Q 0 NN N ,-N H - N 8an 92 4.10 575.4 0 N ~N ~ C S I - N 8ao 97 4.17 613.4 8ap 99 3.64 584.5 No N WO 2007/060404 PCT/GB2006/004327 - 98 Purity Retention [m/z] (%) time (mins) 8aq 99 3.79 523.4 0 HO,,<H N, HNN 00 8ar 98 4.10 629.5 Ho N 0 HO ,HN 0 N N N N N -0 8as 99 4.20 650.5 N NN 0 8at 99 4.11 600.4 0 ). 8au 86 4.20 614.4 01Ne 0 NN N N Nl N. .110 '0 1 WO 2007/060404 PCT/GB2006/004327 - 99 Purity Retention [m/z] (%) ime (mins) 8ay 94 4.20 581.5 8aw 99 4.33 623.4 0 ' aSCI 8ax 99 4.17 589.4 350Q -ay 83 4.22 626.5 00 8az 96 4.41 631.5 IN N NJI WO 2007/060404 PCT/GB2006/004327 -100 Purity Retention [nlrz] (%) time (mins) 8ba 89 5.14 647.5 K 0 H I N N)N 8bb 99 3.95 601.4 HO H NI 8bc 99 4.27 583.4 NoN IN 8bd 99 3.97 583.4 H N 0 00 8be 99 4.29 613.5 0 H N~ H N, I"N 00 WO 2007/060404 PCT/GB2006/004327 - 101 Purity Retention [m/z] (%) time (mins) 8bf 74 10.36 627.6 .... N N N N 0 8bg 93 7.13 599.2 Example 9 R2=aryl ; R7=aryl (Examples 9a - 9ae) To the appropriate 2-chloro-pyridopyrimidine (Inter. 8a)(1 equiv) in acetonitril/water 5 (1:1 ratio - 0.025 M) was added the appropriate boronic acid or ester (1 equiv), potassium carbonate (3.5 equiv) and tetrakis(triphenylphosphine) palladium (0.05 equiv). The mixture was heated to 95 'C under an inert atmosphere for 2 hours whereupon it was cooled to room temperature. The reaction was then filtered through a thin silica pad, which was washed with 1:1 mixture MeOH/CH 2

C

2 (1 volume), concentrated in vacuo and then purified by 10 preparative HPLC to give the desired product (9a-9ae) Purity Retention [m/z] (%) time (mins) 9a - 92 7.17 488.3 .N/ OH i7 N OH 0 WO 2007/060404 PCT/GB2006/004327 - 102 Purity Retention [m/z] (%) time (mins) 9b 86 10.16 518.3 OH N 0i 0 -. 9c 0 95 10.72 474.3 'o) ai ,N 0 0 0 -? 9d 99 4.58 443.4 N K- N 9e 95 4.53 459.4 NH N ,o 9f 97 7.21 419.3

~~

0 83 4.35 457. 9g 83 4.35 457.3

OH

WO 2007/060404 PCT/GB2006/004327 -103 Purity Retention [m/z] (%) ime (mins) 9h ' 97 4.42 473.5 H N 9i 97 4.01 445.3 OH 9j "91 4.70 454.3 9k 79 7.19 472.3 89 7.24 444.3 NN 9m 98 4.45 433.2 9mH 0- cN WO 2007/060404 PCT/GB2006/004327 -104 Purity Retention [m/z] (%) time (mins) 9n 99 3.54 458.3 OH N N 9o 96 11.05 505.3 OH N N F 9p 98 7.49 471.2 N F 9q 92 4.63 489.3 9r OH N N C N N F F 99 11.32 497.3 9s WO 2007/060404 PCT/GB2006/004327 -105 Purity Retention [m/z] (%) time (mins) a94 5.20 404.2 a 99 7.18 448.2 9w 9x 0 ~ ~N 9y or81 5.83 4317.2 ~.99 7.18 448.2 9w 'N 99 5.8 393.2 WO 2007/060404 PCT/GB2006/004327 - 106 Purity Retention [m/z] (%) time (mins) 9z N. N I80 2.71 447.2 cO CI 9ab 96 6.20 428.3 N 9ac N NH c No 97 2.11 446.2 0 cr 9ad 0 9aN 0, 95 6.51 461.2 9ae OH 8N ,,1 I 87 7.28 459.3

H

WO 2007/060404 PCT/GB2006/004327 - 107 Example 10 Enzyme Assay For mTOR enzyme activity assays, mTOR protein was isolated from HeLa cell cytoplasmic extract by immunoprecipitation, and activity determined essentially as described 5 previously using recombinant PHAS-1 as a substrate (ref. 21). The following compounds were tested in this assay:- la, lb, 1c, ld, le, If, 1g, lh, lj, 1k, 11, 11, lm, In, lo, lp, lq, Ir, ls, It, lu, lv, 1w, lx, ly, lz, laa, lab, lac, lad, lae, laf, lag, lah, lai, laj, lak, lal, lam, lan, lao, lap, laq, lar, las, lat, lau, lay, law, lax, lay, laz, lba, lbb, lbc, 2a, 2b, 2c, 2d, 2e, 2f, 2g, 2h, 2i, 2j, 2k, 21, 2m, 2n, 2o, 2p, 2q, 2r, 2s, 2t, 10 2u, 2v, 2w, 2x, 2y, 2z, 2aa, 2ab, 2ac, 2ad, 2ae, 2af, 2ag, 2ah, 2ai, 2aj, 2ak, 2al, 2am, 2an, 2ao, 2ap, 2aq, 2ar, 2as, 2at, 2au, 2av, 2aw, 2ax, 2ay, 2az, 2ba, 2bb, 2be, 2bd, 2be, 2bf, 2bg, 8bm, 8bn, 4a, 5a, 5b, 5c, 5d, 5e, 5f, 5g, 6, 7, 8a, 8b, 8c, 8d, 8e, 8f, 8g, 8h, 8i, 8j, 8k, 81, 8m, 8n, 8o, 8p, 8q, 8r, 8s, 8t, 8u, 8v, 8w, 8x, 8y, 8z, 8aa, 8ab, 8ac, 8ad, 8ae, 8af, 8ag, 8ah, 8ai, 8aj, 8ak, 8al, 8am, 8an, 8ao, 8ap, 8aq, 8ar, 8as, 8at, 8au, 8ay, 8aw, 8ax, 8az, 8ba, 8bb, 8bc, 8bd, 8be, 15 8bf and 8bg. All the compounds tested exhibited IC 50 values against mTOR of less than 10dm. The following compounds exhibited IC 50 values against mTOR of less than 1 [in: laa, lab, lac, lad, lae, laf, lag, lah, lai, laj, lal, lam, lan, lao, lap, laq, lar, las, lat, lau, lay, law, lax, Ic, lk, lr, Is, It, lu, lv, 1w, lx, ly, lz, 2a, 2aa, 2ac, 2ad, 2af, 2ah, 2ap, 2aq, 20 2ar, 2as, 2av, 2aw, 2ax, 2az, 2b, 2bb, 2bd, 2be, 2c, 2e, 2g, 2h, 2i, 2j, 2k, 2n, 2p, 2q, 2t, 2u, 2z, 2bi, 3a, 3b, 5c, 8p, 8q, 8r, 8s, 8t, 8u, 8v, 8w, 8x, 8y, 8ae, 8af, 8am, 8ao, 8at, 8au, 8ay, 8az, 8ba, 8bd and 8bf, with the following compounds exhibiting IC 50 values against mTOR of less than 100nM: la, lb, ld, le, If, 1g, li, 1k, 11, lm, ln, lo, lp, lq, lbb, lbc, 2ba, 8a, 8b, 8c, 8d, 8e, 8f, 8g, 8h, 8i, 8j, 8k, 81, 8m, 8n, 8o, 8aa, 8ab, 8ac, 8ad, 8ag, 8ah, 8ai, 8aj, 8ak, 8al, 8an, 25 8ap, 8aq, 8ar, 8as, 8av, 8aw, 8ax, 8bb, 8bc, 8be, 8bg. For example, Compound 1k has an IC 50 of 0.043pM Example 11 Alternative Enzyme Assay The assay used AlphaScreen technlmology (Gray et al., Analytical Biochemistry, 2003, 30 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR. A C-terminal truncation of mTOR encompassing amino acid residues 1362 to 2549 of mTOR (EMBL Accession No. L34075) was stably expressed as a FLAG-tagged fusion in WO 2007/060404 PCT/GB2006/004327 - 108 HEK293 cells as described by Vilella-Bach et al., Journal of Biochemistry, 1999, 274, 4266 4272. The HEK293 FLAG-tagged mTOR (1362-2549) stable cell line was routinely maintained at 37°C with 5% CO 2 up to a confluency of 70-90% in Dulbecco's modified Eagle's growth medium (DMEM; Invitrogen Limited, Paisley, UK Catalogue No. 41966-029) 5 containing 10% heat-inactivated foetal calf serum (FCS; Sigma, Poole, Dorset, UK, Catalogue No. F0392), 1% L-glutamine (Gibco, Catalogue No. 25030-024) and 2 mg/ml Geneticin (G418 sulphate; Invitrogen Limited, UK Catalogue No. 10131-027). Following expression in the mammalian HEK293 cell line, expressed protein was purified using the FLAG epitope tag using standard purification techniques. 10 Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 [l) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 30 pl mixture of recombinant purified mTOR enzyme, 1 pM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe 15 Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 pM) and a buffer solution [comprising Tris-HCI pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] was agitated at room temperature for 90 minutes. Control wells that produced a maximum signal corresponding to maximum enzyme 20 activity were created by using 5% DMSO instead of test compound. Control wells that produced a minimum signal corresponding to fully inhibited enzyme were created by adding EDTA (83 mM) instead of test compound. These assay solutions were incubated for 2 hours at room temperature. Each reaction was stopped by the addition of 10 gl of a mixture of EDTA (50 mM), 25 bovine serum albumin (BSA; 0.5 mg/ml) and Tris-HCl pH7.4 buffer (50 mM) containing p 7 0 S6 Kinase (T389) 1AS Monoclonal Antibody (Cell Signalling Technology, Catalogue No. 9206B) and AlphaScreen Streptavidin donor and Protein A acceptor beads (200 ng; Perkin Elmer, Catalogue No. 6760002B and 6760137R respectively) were added and the assay plates were left for about 20 hours at room temperature in the dark. The resultant 30 signals arising from laser light excitation at 680 nm were read using a Packard Envision instrument. Phosphorylated biotinylated peptide is formed in situ as a result of mTOR mediated phosphorylation. The phosphorylated biotinylated peptide that is associated with WO 2007/060404 PCT/GB2006/004327 - 109 AlphaScreen Streptavidin donor beads forms a complex with the p70 S6 Kinase (T389) 1A5 Monoclonal Antibody that is associated with Alphascreen Protein A acceptor beads. Upon laser light excitation at 680 nm, the donor bead : acceptor bead complex produces a signal that can be measured. Accordingly, the presence of mTOR kinase activity results in an assay 5 signal. In the presence of an mTOR kinase inhibitor, signal strength is reduced. mTOR enzyme inhibition for a given test compound was expressed as an IC 50 value. The following compounds were screened in this assay:- lbd, 1be, lbk, lbl, lbm, lbn, lbo, lbp, lbq, lbr, lbs, lbt, lbu, 1by, lbw, lbx, 2bf, 9a, 9b, 9c, 9d, 9e, 9f, 9g, 9i, 9j, 9m, 9n, 90, 9p, 9q, 9r, 9s, 9t, 9u, 9v, 9w, 9x, 9y, 9z, 9aa, 9ab, 9ac, 9ad and 9ae. 10 All the compounds tested exhibited IC 50 values against mTOR of less than 10p[m. The following compounds exhibited ICs 50 values against mTOR of less than 1 lm: lbk, lbm, lbn, lbo, lbp, lbq, lbr, lbs, lbt, lbu, 9m, 9n, 9p, 9r, 9aa and 9ad, with the following compounds exhibiting IC 50 values against mTOR of less than 300nM: lbd, lbe, 9a, 9b, 9c, 9d, 9e, 9f, 9g, 9ae, 91, 9j, 9k, 9i, 9h, lbj, lbi, lbh, lbg and lbf. For example, Compound lb 15 has an IC 50 of 0.057tpM Example 12 Cell proliferation assay (Gs1 50 ) Cell growth was assessed using the sulforhodamine B (SRB) assay (A). T47D 20 (ECACC, 85102201) cells were routinely passaged in RPMI (Invitrogen, 42401018) plus 10% foetal calf serum (FCS), 1% L-glutamine (Gibco BRL, 25030) to a confluence not greater than 80%. To undertake the assay, T47D cells were seeded at 2.5x10 3 cells/ well in 90pl RPMI plus 10% foetal calf serum, 1% L-glutamine in 96 well plates (Costar, 3904) and incubated at 37 0 C (+5% CO 2 ) in a humidified incubator. Once the cells had fully adhered 25 (typically following 4-5 hours incubation) the plate was removed from the incubator and 10pL of the diluent added to the control wells (Al-12 and Bl-12). Compound was prepared in a six point semi-log dilution at 10x the final concentration required e.g. for a 6 point range of 30pM to 100nM in semi-log steps dilution started at 300ptM in stock plate. Dosing was completed by addition of 10tL of compound at highest concentration to C1-12 through to the 30 lowest concentration in H1-12. The plates were then incubated for 120 hours prior to SRB analysis. Upon completion of incubation, media was removed and the cells fixed with 100pl of ice cold 10% (w/v) trichloroacetic acid. The plates were incubated at 4C for 20 minutes and WO 2007/060404 PCT/GB2006/004327 - 110 then washed four times with water. Each well of cells was then stained with 100[tl of 0.4% (w/v) SRB (Sulforhodamine B, Sigma, Poole, Dorset, UK, Catalogue number S-9012) in 1% acetic acid for 20 minutes before washing four times with 1% acetic acid. Plates were then dried for 2 hours at room temperature. The dye from the stained cells was solubilized by the 5 addition of 100pl of 10mM Tris Base into each well. Plates were gently shaken and left at room temperature for 30 minutes before measuring the optical density at 564nM on a Microquant microtiter plate reader. The concentration of inhibitor eliciting a 50% reduction in growth (G 5 Is 0 ) was determined by analysis of staining intensity of the treated cells as a percentage of the vehicle control wells using Excelfit software. 10 (A) Skehan, P., Storung, R., Scudiero, R., Monkls, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenny, S. and Boyd, M. R. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112. 15 All the compounds tested exhibited G 5 Is 0 values of less than 10pM. The following compounds exhibited G 5 Is 0 values of less than 1 pM 8c, 8e, 8h, 8m, 8n, 8o, 8p, 8q, 8s, 8v, 8w, 8x, 8y, 8z, 8aa, and 8ac, with the following compounds exhibiting G 5 Is 0 values of less than 300nM : lg, 8a, 8b, 8d, 8f, 8g, 8i, 8k, 81, 8r, 8t, 8u, 8ab, 8ad, 8ae, 8af, 8ag, 8ah, 8ai, 8aj, 8ak, 8al, 8am, 8an, 8ao, 8ap, 8aq, 8ar, 8as, 8at, 8au, 8av, 8aw, 8ax, 8ay, 8az, 8ba, 20 8bb, 8be, 8bd, 8be, 8bf, and 8bg. For example, Compound lr has a GIso of 0.232PM. Example 13 In Vitro phospho-Ser473 Akt assay This assay determines the ability of test compounds to inhibit phosphorylation of 25 Serine 473 in Akt as assessed using Acumen Explorer technology (Acumen Bioscience Limited), a plate reader that can be used to rapidly quantitate features of images generated by laser-scanning. A MDA-MB-468 human breast adenocarcinoma cell line (LGC Promochem, Teddington, Middlesex, UK, Catalogue No. HTB-132) was routinely maintained at 37'C with 30 5% CO 2 up to a confluency of 70-90% in DMEM containing 10% heat-inactivated FCS and 1% L-glutamine. For the assay, the cells were detached from the culture flask using 'Accutase' (Innovative Cell Technologies Inc., San Diego, CA, USA; Catalogue No. AT104) using standard tissue culture methods and resuspended in media to give 1.7x105 cells per ml.

WO 2007/060404 PCT/GB2006/004327 - 111 Aliquots (90 il) were seeded into each of the inner 60 wells of a black Packard 96 well plate (PerldkinElmer, Boston, MA, USA; Catalogue No. 6005182) to give a density of ~15000 cells per well. Aliquots (90 pl) of culture media were placed in the outer wells to prevent edge effects. The cells were incubated overnight at 37 0 C with 5% CO 2 to allow them to adhere. 5 On day 2, the cells were treated with test compounds and incubated for 2 hours at 37°C with 5% CO 2 . Test compounds were prepared as 10 mM stock solutions in DMSO and serially diluted as required with growth media to give a range of concentrations that were 10 fold the required final test concentrations. Aliquots (10 pl) of each compound dilution were placed in a well (in triplicate) to give the final required concentrations. As a minimum 10 reponse control, each plate contained wells having a final concentration of 100 tM LY294002 (Calbiochem, Beeston, UK, Catalogue No. 440202). As a maximum response control, wells contained 1% DMSO instead of test compound. Following incubation, the contents of the plates were fixed by treatment with a 1.6% aqueous formaldehyde solution (Sigma, Poole, Dorset, UK, Catalogue No. F1635) at room temperature for 1 hour. 15 All subsequent aspiration and wash steps were carried out using a Tecan 96 well plate washer (aspiration speed 10 mm/sec). The fixing solution was removed and the contents of the plates were washed with phosphate-buffered saline (PBS; 50 pl; Gibco, Catalogue No. 10010015). The contents of the plates were treated for 10 minutes at room temperature with an aliquot (50 pl) of a cell permeabilisation buffer consisting of a mixture of PBS and 0.5% 20 Tween-20. The 'permeabilisation' buffer was removed and non-specific binding sites were blocked by treatment for 1 hour at room temperature of an aliquot (50 gl) of a blocking buffer consisting of 5% dried skimmed milk ['Marvel' (registered trade mark); Premier Beverages, Stafford, GB] in a mixture of PBS and 0.05% Tween-20. The 'blocking' buffer was removed and the cells were incubated for 1 hour at room temperature with rabbit anti phospho-Akt 25 (Ser473) antibody solution (50 pl per well; Cell Signalling, Hitchin, Herts, U.K., Catalogue No 9277) that had been diluted 1:500 in 'blocking' buffer. Cells were washed three times in a mixture of PBS and 0.05% Tween-20. Subsequently, cells were incubated for 1 hour at room temperature with Alexafluor488 labelled goat anti-rabbit IgG (50 pl per well; Molecular Probes, Invitrogen Limited, Paisley, UK, Catalogue No. Al 1008) that had been diluted 1:500 30 in 'blocking' buffer. Cells were washed 3 times with a mixture of PBS and 0.05% Tween-20. An aliquot of PBS (50 pl) was added to each well and the plates were sealed with black plate sealers and the fluorescence signal was detected and analysed.

WO 2007/060404 PCT/GB2006/004327 - 112 Fluorescence dose response data obtained with each compound were analysed and the degree of inhibition of Serine 473 in Akt was expressed as an IC 50 value. The following compounds were tested and exhibited a cellular IC 50 , measured by pAkt, of less than 25pM: lbj, lbd, lbh, lbi, 9j, 9a, 9aa, 9r, 9d, 9f, 9e with the following compounds 5 exhibiting a cellular IC 50 , measured by pAkt, of less than 2.5pM: lbr, lbg, lbe, 91, 9n, 9k, 9h, 9g, 9m and 9i. For example, compound 91 has a pAkt IC50 of 2.2uM 10 WO 2007/060404 PCT/GB2006/004327 - 113 Reference List The following documents are all herein incorporated by reference. 1) Brown, et al., Nature, 369, 756-758 (1994) 5 2) Chiu, et al., Proc NatlAcadSci, 91, 12574-12578 (1994) 3) Sabatini, et al., Cell, 78, 35-43, (1994) 4) Sabers, et al., JBiol Chem, 270, 825-822 (1995) 5) Abraham, Curr Opin Immunol, 8, 412-418 (1996) 6) Schmelze and Hall, Cell, 103, 253-262 (2000) 10 7) Burnett, et al., Proc NatlAcad Sci, 95, 1432-1437 (1998) 8) Terada, et al., Proc NatlAcad Sci, 91,11477-11481 (1994) 9) Jeffries, et al., EMBO J, 16,3693-3704 (1997) 10) Bjornsti and Houghton, Nat Rev Cancer, 4, 335-348 (2004) 11) Gingras, et al., Genes Dev, 13, 1422-1437 (1999) 15 12) Gingras, et al., Genes Dev, 15, 807-826 (2001) 13) Neuhaus, et al., Liver Transplantation, 7, 473-484 (2001) 14) Woods and Marks, Ann Rev Med, 55, 169-178 (2004) 15) Dahia, Endocrine-Related Cancer, 7, 115-129 (2000) 16) Cristofano and Pandolfi, Cell, 100, 387-390 (2000) 20 17) Samuels, et al., Science, 304, 554 (2004) 18) Huang and Houghton, Curr Opin Pharmacol, 3, 371-377 (2003) 19) Sawyers, Cancer Cell, 4, 343-348 (2003) 20) Huang and Houghton, Curr Opin in Invest Drugs, 3, 295-304 (2002) 21) Brunn, et al., EMBO J, 15, 5256-5267 (1996) 25 22) Edinger, et al., Cancer Res, 63, 8451-8460, (2003) 23) Lawrence, et al., Curr Top Microbiol Immunol, 279, 199-213 (2004) 24) Eshleman, et al., Cancer Res, 62, 7291-7297 (2002) 25) Berge, et al., J Pharm. Sci., 66, 1-19 (1977). 26) Green, T. and Wuts, P., "Protective Groups in Organic Synthesis", 3rd Edition, John 30 Wiley and Sons (1999). 27) "Handbook of Pharmaceutical Additives", 2nd Edition (eds. M. Ash and I. Ash), 2001 (Synapse Information Resources, Inc., Endicott, New York, USA).

WO 2007/060404 PCT/GB2006/004327 -114 28) "Remington's Pharmaceutical Sciences", 20th edition, pub. Lippincott, Williams & Wilkins, 2000. 29) "Handbook of Pharmaceutical Excipients", 2nd edition, 1994. 5

Claims (53)

1. A compound of formula I: N4 N3 R 1- NR R X N R 2 5 wherein: one or two of X 5 , X 6 and X 8 is N, and the others are CH; R is selected from halo, ORO', SR s , NRIR N2 , NRN 7 aC(=O)RcI, NRN 7 bSO 2 Rs 2 a, an optionally substituted C 5 - 2 0 heteroaryl group, or an optionally substituted C5- 20 aryl group, where Rol and R s ' are selected from H, an optionally substituted C 5 - 20 aryl group, an 10 optionally substituted C 5 - 20 heteroaryl group, or an optionally substituted C 1 - 7 alkyl group; RNI and R N2 are independently selected from H, an optionally substituted Cl- 7 alkyl group, an optionally substituted C 5 - 20 heteroaryl group, an optionally substituted C 5 - 20 aryl group or R and RN 2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; 15 R c l is selected from H, an optionally substituted C 5 - 20 aryl group, an optionally substituted C5-. 2o heteroaryl group, an optionally substituted C 1 - 7 alkyl group or NRSR N 9, where R 8 and R N9 are independently selected from H, an optionally substituted CI-7 alkyl group, an optionally substituted C 5 - 20 heteroaryl group, an optionally substituted C 5 - 20 aryl group or RN 8 and RN 9 together with the nitrogen to which they are bound form a heterocyclic ring containing 20 between 3 and 8 ring atoms; Rs 2 a is selected from H, an optionally substituted C 5 - 20 aryl group, an optionally substituted C 5 - 20 heteroaryl group, or an optionally substituted C.-7 alkyl group; RN 7 a and RN 7 b are selected from H and a C 1 - 4 alkyl group; RN 3 and RN 4 , together with the nitrogen to which they are bound, form a heterocyclic ring 25 containing between 3 and 8 ring atoms; R 2 is selected from H, halo, OR 0 2 , SRS 2 b, NRN5RN 6 , an optionally substituted C 5 - 20 heteroaryl group, and an optionally substituted C5- 20 aryl group, wherein R O 2 and RS 2 b are selected from H, an optionally substituted C5- 20 aryl group, an optionally substituted C 5 - 20 heteroaryl group, or an optionally substituted C.-7 alkyl group;; 30 RN 5 and RN 6 are independently selected from H, an optionally substituted C 1 .- 7 alkyl group, an optionally substituted C 5 - 20 heteroaryl group, and an optionally substituted C 5 - 20 aryl group, or WO 2007/060404 PCT/GB2006/004327 - 116 R 5 and RN 6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, or a pharmaceutically acceptable salt thereof, with the proviso that when R 2 is unsubstituted morpholino, RN 3 and RN 4 together with the 5 nitrogen atom to which they are attached form an unsubstituted morpholino and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not N and X 8 is not CH, or X 6 is not CH and X 8 is not N, and when R 2 is unsubstituted piperidinyl, RN 3 and RN 4 together with the nitrogen atom to which they are attached form an unsubstituted piperidinyl and R 7 is unsubstituted phenyl, and X 5 is 10 CH, then X 6 is not CH and X 8 is not N.

2. A compound according to claim 1, wherein only one of X 5 , X 6 and X 8 is N.

3. A compound according to claim 2, wherein X 8 is N. 15

4. A compound according to any one of the preceding claims, wherein R 7 is selected from an optionally substituted C5- 20 aryl group, OR o1 , NRN IR N2 , RN 7 aC(=O)R c I and NRN 7 bSO 2 RS 2 a 20

5. A compound according to any one of claims 1 to 4, wherein R7 is an optionally substituted phenyl group.

6. A compound according to any one of claims 1 to 4, wherein R 7 is ORo l , and Ro l is a C 1 - 7 alkyl group, which may be substituted. 25

7. A compound according to any one of claims 1 to 4, wherein R7 is NRN R N 2 , and RN 2 is H.

8. A compound according to claim 5, wherein R 7 is a phenyl goup optionally substituted 30 by one or more groups selected from chloro, hydroxyl, methyl, methoxy, ethoxy, i-propoxy, benzyloxy and hydroxymethyl. WO 2007/060404 PCT/GB2006/004327 -117

9. A compound according to claim 8, wherein R 7 is 4-chlorophenyl, 4-methylphenyl, 4 methoxyphenyl, 3-hydroxymethyl-4-methoxy-phenyl, 3,5-dimethoxy-4-hydroxyphenyl, 4 hydroxyphenyl, 3-hydroxyphenyl or a 3-hydroxymethylphenyl group. 5

10. A compound according to claim 7, wherein RNI is C 3 - 7 cycloalkyl.

11. A compound according to claim 7, wherein RN! is C5-6 aryl.

12. A compound according to any one of claims 1 to 4, wherein R 7 is NRN 7 aC(=O)RcI, 10 and RN 7 a is preferably H.

13. A compound according to claim 12, wherein R c l is selected from an optionally substituted C 5 - 20 aryl group, C 3 - 20 heterocyclyl, C 1 -7 alkyl and NRN RN 9 , where RN 8 is hydrogen, and RN 9 is C1- 7 alkyl. 15

14. A compound according to any one of claims 1 to 4, wherein R 7 is NRN 7 bSO 2 RS 2 a, and RN7b is H.

15. A compound according to claim 14, wherein R S2 a is C1- 7 alkyl. 20

16. A compound of formula I(A): N4 N3 N10 5 N H X 6 ' XN 0 3 X 8 N R R 0 R 1(A) wherein: one or two of X 5 , X 6 and X 8 is N, and the others are CH; 25 RN 3 and RN 4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms; R 2 is selected from H, halo, OR 0 2 , SRs 2 b, NRNSRN 6 , an optionally substituted C 5 - 20 heteroaryl group, and an optionally substituted C 5 - 20 afyl group, WO 2007/060404 PCT/GB2006/004327 -118 wherein Ro 2 and RS 2 b are selected from H, an optionally substituted C 5 - 20 aryl group, an optionally substituted C 5 - 20 heteroaryl group, or an optionally substituted C.-7 alkyl group; RNs 5 and RN 6 are independently selected from H, an optionally substituted C.- 7 alkyl group, an optionally substituted C5- 20 heteroaryl group, and an optionally substituted C 5 - 20 aryl group, or 5 RN 5 and RN 6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R 0 3 is selected from hydrogen or an optionally substituted CI-6 alkyl group; and R N 0 is selected from C(=O)RC 2 , C(=S)RC 3 , S0 2 R S3 , an optionally substituted C 5 - 20 heteroaryl group, an optionally substituted C 5 - 20 aryl group, or an optionally substituted C 1 -o 1 0 alkyl group 10 where R C2 and Rc 3 are selected from H, an optionally substituted C5- 20 aryl group, an optionally substituted C 5 - 20 heteroaryl group, an optionally substituted C.-7 alkyl group or NR R N I2, where RN" 1 1 and RN1 2 are independently selected from H, an optionally substituted C.-7 alkyl group, an optionally substituted C 5 - 20 heteroaryl group, an optionally substituted C 5 - 20 aryl group or RN 11 and RNI 2 together with the nitrogen to which they are bound form a 15 heterocyclic ring containing between 3 and 8 ring atoms; and R s 3 is selected from H, an optionally substituted C 5 - 20 aryl group, an optionally substituted C 5 - 20 heteroaryl group, or an optionally substituted Cl- 7 alkyl group, or a pharmaceutically acceptable salt thereof. 20

17. A compound according to claim 16, wherein only one of X 5 , X 6 and X 8 is N.

18. A compound according to claim 17, wherein X 8 is N.

19. A compound according to any one of claims 16, 17 or 18, wherein R N I is selected 25 from C(=S)RC 3 , an optionally substituted C 5 - 20 heteroaryl group, an optionally substituted C5 20 aryl group, and an optionally substituted CI- 10 alkyl group.

20. A compound according to any one of claims 16 to 19, wherein RN I o is C(=S)RC 3 , and wherein Rc 3 is NRNI RN 12, where RN 1 1 and RN I2 together with the nitrogen to which they are 30 bound form a heterocyclic ring containing between 3 and 8 ring atoms.

21. A compound according to any one of claims 16 to 19, wherein RN 10 is a C 5 - 6 heteroaryl group which may be substituted. WO 2007/060404 PCT/GB2006/004327 -119

22. A compound according to claim 21 wherein RNo is an optionally substituted pyrazole group, wherein the optional substituents are selected from halo, hydroxyl, C,-7 alkyl and C 1 .- 7 alkoxy. 5

23. A compound according to any one of claims 16 to 19, wherein RN 10 is a C 5 -6 aryl group which may be substituted.

24. A compound according to claim 23, wherein RN 1 o is an optionally substituted phenyl 10 group, wherein the optional substituents are preferably selected from halo, hydroxyl, CI.-7 alkyl and C.-7 alkoxy.

25. A compound according to any one of claims 16 to 19, wherein RN 1 o is an optionally substituted C 1 . 6 alkyl group, wherein the optional substituents are preferably selected from 15 halo, hydroxyl, Ci.-7 alkyl, ether, for example C 1 -7 alkoxy, thioether, for example Ct-7 alkylthio, C 5 - 20 aryl, C 3 - 20 heterocyclyl, C 5 - 20 heteroaryl, cyano, ester, for example -C(=O)OR where R is CI.7alkyl, and amino, for example CI.7alkylamino, di-Ci.-alkylamino and C 1 . 7alkoxycarbonylamino. 20

26. A compound according to any one claims 16 to 25 wherein R 0 3 is an optionally substituted C 1 .- 6 alkyl group.

27. A compound according to claim 26, wherein Ro 3 is an unsubstituted CI. 3 alkyl group. 25

28. A compound according to claim 27, wherein R 0 3 is a methyl group.

29. A compound according to any one of the preceding claims, wherein RN 3 and RN 4 together with the nitrogen to which they are bound form a heterocyclic ring containing between 5 and 7 ring atoms, which may optionally be substituted. 30

30. A compound according to claim 29 wherein RN 3 and RN 4 together with the nitrogen to which they are bound form a morpholino group. WO 2007/060404 PCT/GB2006/004327 - 120

31. A compound according to any one of the preceding claims, wherein R 2 is NRNSRN 6 where RN 5 and RN 6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, which may optionally be substituted. 5

32. A compound according to claim 31, wherein R 2 is selected from optionally substituted morpholino, thiomorpholino, piperidinyl, piperazinyl, homopiperazinyl and pyrrolidinyl.

33. A compound according to claim 32, wherein R 2 is S or or 10

34. A compound selected from any of Examples la, lb, Id, le, If, 1g, li, 1k, 11, lm, In, lo, lp, lq, lbb, lbc, lbd, Ibe, lbf, lbg, lbh, lbi, lbj, lbr, 8a, 8b, 8c, 8d, 8e, 8f, 8g, 8h, 8i, 8j, 8k, 81, 8m, 8n, 8o, 8t, 8u, 8aa, 8ab, 8ac, 8ad, 8ae, 8af, 8ag, 8ah, 8ai, 8aj, 8ak, 8al, 8am, 8an, 15 8ao, 8ap, 8aq, 8ar, 8as, 8at, 8au, 8av, 8aw, 8ax, 8ay, 8az, 8ba, 8bb, 8bc, 8bd, 8be, 8bg, 9a, 9b, 9c, 9d, 9e, 9f, 9g, 9h, 9i, 9j, 9k, 91, 9m, 9n and 9ae, or pharmaceutically acceptable salts thereof.

35. A pharmaceutical composition comprising a compound according to any one of claims 20 1 to 34, and a pharmaceutically acceptable carrier or diluent.

36. A compound according to any one of claims 1 to 34 for use in a method of treatment of the human or animal body. 25

37. The use of a compound according to any one of claims 1 to 34 without the provisos in the preparation of a medicament for treating a disease ameliorated by the inhibition of mTOR.

38. A compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, for use as a medicament. 30 WO 2007/060404 PCT/GB2006/004327 - 121

39. The use of a compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the production of a mTOR inhibitory effect in a warm-blooded animal such as man. 5

40. The use of a compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as man.

41. The use of a compound according to any one of claims 1 to 34, or a pharmaceutically 10 acceptable salt thereof, in the manufacture of a medicament for use in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries. 15

42. The use of a compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, in the production of a mTOR inhibitory effect in a warm-blooded animal such as man. 20

43. The use of a compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, in the production of an anti-cancer effect in a warm-blooded animal such as man.

44. The use of a compound according to any one of claims 1 to 34, or a pharmaceutically 25 acceptable salt thereof, in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries. 30

45. A method for producing a mTOR inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective WO 2007/060404 PCT/GB2006/004327 - 122 amount of a compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof.

46. A method for producing an anti-cancer effect in a warm-blooded animal, such as man, 5 in need of such treatment which comprises administering to said animal an effective amount of a compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof.

47. A method of treating melanoma, papillary thyroid tumours, cholangiocarcinomas, 10 colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound according to any one of claims 1 to 34, or a 15 pharmaceutically acceptable salt thereof.

48. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier for use in the production of a mTOR inhibitory 20 effect in a warm-blooded animal such as man.

49. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier for use in the production of an anti-cancer 25 effect in a warm-blooded animal such as man.

50. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of melanoma, papillary 30 thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries in a warm-blooded animal such as man. WO 2007/060404 PCT/GB2006/004327 - 123

51. A process for the preparation of a compound of formula 1, from a compound of Formula 2: R 4 5 X6x C I 2N Formula 2 CI X N R 5 wherein: R 4 is NRN 3 RN 4 where RN 3 and RN 4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms; R2 is selected from H, halo, OR 0 2 , SRS 2 b, NRNSRN 6, an optionally substituted C 5 - 20 heteroaryl group, and an optionally substituted C 5 - 20 aryl group, 10 wherein RO2 and Rs 2 b are selected from H, an optionally substituted C5- 2 0 aryl group, an optionally substituted C5- 20 heteroaryl group, or an optionally substituted CI- 7 alkyl group, and R N and RN 6 are independently selected from H, an optionally substituted CI.- 7 alkyl group, an optionally substituted C 5 - 20 heteroaryl group, and an optionally substituted C 5 -2 0 aryl group, or RN 5 and RN 6 together with the nitrogen to which they are bound form a heterocyclic ring 15 containing between 3 and 8 ring atoms, comprising (e) when R 7 is NRN RN 2 , reaction of the compound of formula 2 with R 7 H; or (f) when R7 is an optionally substituted C 3 - 20 heterocyclyl group or C5- 20 aryl group, reaction of the compound of formula 2 with R 7 B(OAlk) 2 , where each Alk is 20 independently CI- 7 alkyl or together with the oxygen to which they are attached form a C 5 .- 7 heterocyclyl group, or (g) when R7 is an amide, urea or sulfonamide group, reaction of a compound of formula 2 with ammonia followed by reaction of the resulting primary amine with the appropriate acid chloride, isocyanate or sulfonyl chloride, or 25 (h) when R 7 is ORO 1 or SR s1 , by reaction of the compound of formula 1 in the presence of base in the appropriate alcohol or thiol solvent.

52. A process for the preparation of a compound of formula I(A) comprising reacting a compound of Formula la: WO 2007/060404 PCT/GB2006/004327 - 124 R4 X 6 N R Formula la R2 R 7 X 8 N5 R wherein R 4 represents NRN 3 RN 4 , and Lv 03 RN / R 7 is , wherein Lv is a leaving group, such as a halogen, for example chlorine, or an OSO 2 R group, where R is alkyl or aryl, such as methyl, 5 with RNIoNH 2 .

53. A process for the preparation of a compound of formula 1 from a compound of formula 2A: R 4 5 x6X N X 'N 61 N Formula 2A R X 8" N 'Cl 10 wherein R 4 is NRN 3 RN 4 where RN 3 and RN 4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms; and R 7 is selected from halo, OR 1 ol, SR s , NRNIRN 2 , NRN7aC(=O)RcI, NRN 7 bSO 2 RS 2 a' an optionally substituted C 5 - 20 heteroaryl group, or an optionally substituted C 5 - 20 aryl group, 15 where Ro 1 and R sl are selected from H, an optionally substituted C5- 20 aryl group, an optionally substituted C5- 20 heteroaryl group, or an optionally substituted CI- 7 alkyl group; RNI and RN 2 are independently selected from H, an optionally substituted C 1 .- 7 alkyl group, an optionally substituted C 5 - 20 heteroaryl group, an optionally substituted C5- 20 aryl group or RN and RN 2 together with the nitrogen to which they are bound form a heterocyclic ring 20 containing between 3 and 8 ring atoms; R c l is selected from H, an optionally substituted Cs- 20 aryl group, an optionally substituted C5-. 20 heteroaryl group, an optionally substituted C.-7 alkyl group or NRN 8 RN 9 , where RN' and RN 9 are independently selected from H, an optionally substituted C 1 .- 7 alkyl group, an optionally substituted C 5 - 20 heteroaryl group, an optionally substituted C5- 20 aryl group or RN' and RN' 25 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; WO 2007/060404 PCT/GB2006/004327 - 125 R s2a is selected from H, an optionally substituted C 5 - 20 aryl group, an optionally substituted C 5 - 20 heteroaryl group, or an optionally substituted C 1 - 7 alkyl group; and RN 7 a and RN 7 b are selected from H and a C 1 - 4 alkyl group; comprising 5 (d) when R 2 is NRNSRN 6 , reacting a compound of formula 2A with R 2 H, or (e) when R 2 is an opionally substituted C 3 - 20 heterocyclyl group or C5- 20 aryl group, by reacting a compound of formula 2A with R 2 B(OAlk) 2 , where each Alk is independently C 1 . 7 alkyl or together with the oxygen to which they are attached form a C 5 - 7 heterocyclyl group, or 10 (f) when R 2 is OR 0 2 or SRs 2 b, by reacting a compound of formula 2A in the presence of a base in the appropriate alcohol or thiol solvent.